<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Prophylactic barbiturate use for the prevention of morbidity and mortality following perinatal asphyxia - Young, L - 2016 | Cochrane Library</title> <meta content="Prophylactic barbiturate use for the prevention of morbidity and mortality following perinatal asphyxia - Young, L - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001240.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Prophylactic barbiturate use for the prevention of morbidity and mortality following perinatal asphyxia - Young, L - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001240.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001240.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Prophylactic barbiturate use for the prevention of morbidity and mortality following perinatal asphyxia" name="citation_title"/> <meta content="Leslie Young" name="citation_author"/> <meta content="University of Vermont Medical Center" name="citation_author_institution"/> <meta content="Leslie.Young@vtmednet.org" name="citation_author_email"/> <meta content="Marie Berg" name="citation_author"/> <meta content="University of Vermont Medical Center" name="citation_author_institution"/> <meta content="Roger Soll" name="citation_author"/> <meta content="University of Vermont Medical Center" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD001240.pub3" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/05/05" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001240.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001240.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001240.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticonvulsants [*therapeutic use]; Asphyxia Neonatorum [complications, *drug therapy, mortality]; Barbiturates [*therapeutic use]; Infant, Premature; Neurodevelopmental Disorders [etiology, prevention &amp; control]; Phenobarbital [therapeutic use]; Phenytoin [therapeutic use]; Randomized Controlled Trials as Topic; Seizures [mortality, *prevention &amp; control]; Thiopental [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001240.pub3&amp;doi=10.1002/14651858.CD001240.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001240.pub3&amp;doi=10.1002/14651858.CD001240.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001240.pub3&amp;doi=10.1002/14651858.CD001240.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001240.pub3&amp;doi=10.1002/14651858.CD001240.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001240.pub3&amp;doi=10.1002/14651858.CD001240.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001240.pub3&amp;doi=10.1002/14651858.CD001240.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001240.pub3&amp;doi=10.1002/14651858.CD001240.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001240.pub3&amp;doi=10.1002/14651858.CD001240.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001240.pub3&amp;doi=10.1002/14651858.CD001240.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001240.pub3&amp;doi=10.1002/14651858.CD001240.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001240.pub3&amp;doi=10.1002/14651858.CD001240.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001240.pub3&amp;doi=10.1002/14651858.CD001240.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001240.pub3&amp;doi=10.1002/14651858.CD001240.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001240.pub3&amp;doi=10.1002/14651858.CD001240.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001240.pub3&amp;doi=10.1002/14651858.CD001240.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001240.pub3&amp;doi=10.1002/14651858.CD001240.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001240.pub3&amp;doi=10.1002/14651858.CD001240.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001240.pub3&amp;doi=10.1002/14651858.CD001240.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001240.pub3&amp;doi=10.1002/14651858.CD001240.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001240.pub3&amp;doi=10.1002/14651858.CD001240.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001240.pub3&amp;doi=10.1002/14651858.CD001240.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001240.pub3&amp;doi=10.1002/14651858.CD001240.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001240.pub3&amp;doi=10.1002/14651858.CD001240.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="VXKc2U6b";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001240\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001240\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001240\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001240\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001240.pub3",title:"Prophylactic barbiturate use for the prevention of morbidity and mortality following perinatal asphyxia",firstPublishedDate:"May 5, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neonatal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=VXKc2U6b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001240.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001240.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001240.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001240.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001240.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001240.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001240.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001240.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001240.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001240.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4839 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001240.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001240.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001240.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001240.pub3/full#CD001240-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001240.pub3/full#CD001240-sec-0088"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001240.pub3/full#CD001240-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001240.pub3/full#CD001240-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001240.pub3/full#CD001240-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001240.pub3/full#CD001240-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001240.pub3/full#CD001240-sec-0046"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001240.pub3/full#CD001240-sec-0084"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001240.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001240.pub3/appendices#CD001240-sec-0093"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001240.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001240.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/table_n/CD001240StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/table_n/CD001240StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001240.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001240.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001240.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001240.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001240.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001240.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Prophylactic barbiturate use for the prevention of morbidity and mortality following perinatal asphyxia </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001240.pub3/information#CD001240-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Leslie Young</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001240.pub3/information#CD001240-cr-0003">Marie Berg</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001240.pub3/information#CD001240-cr-0004">Roger Soll</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/information/en#CD001240-sec-0105">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 05 May 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001240.pub3">https://doi.org/10.1002/14651858.CD001240.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001240-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001240-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001240-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001240-abs-0008">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001240-abs-0001" lang="en"> <section id="CD001240-sec-0001"> <h3 class="title" id="CD001240-sec-0001">Background</h3> <p>Seizures are common following perinatal asphyxia and may exacerbate secondary neuronal injury. Barbiturate therapy has been used for infants with perinatal asphyxia in order to prevent seizures. However, barbiturate therapy may adversely affect neurodevelopment leading to concern regarding aggressive use in neonates. </p> </section> <section id="CD001240-sec-0002"> <h3 class="title" id="CD001240-sec-0002">Objectives</h3> <p>To determine the effect of administering prophylactic barbiturate therapy on death or neurodevelopmental disability in term and late preterm infants following perinatal asphyxia. </p> </section> <section id="CD001240-sec-0003"> <h3 class="title" id="CD001240-sec-0003">Search methods</h3> <p>We used the standard search strategy of the Cochrane Neonatal Review group to search the Cochrane Central Register of Controlled Trials (CENTRAL, 2015, Issue 11), MEDLINE via PubMed (1966 to 30 November 2015), EMBASE (1980 to 30 November 2015), and CINAHL (1982 to 30 November 2015). We also searched clinical trials databases, conference proceedings, and the reference lists of retrieved articles for randomized controlled trials (RCT) and quasi‐RCTs. </p> </section> <section id="CD001240-sec-0004"> <h3 class="title" id="CD001240-sec-0004">Selection criteria</h3> <p>We included all RCTs or quasi‐RCTs of prophylactic barbiturate therapy in term and late preterm infants without clinical or electroencephalographic evidence of seizures compared to controls following perinatal asphyxia. </p> </section> <section id="CD001240-sec-0005"> <h3 class="title" id="CD001240-sec-0005">Data collection and analysis</h3> <p>Three review authors independently selected, assessed the quality of, and extracted data from the included studies. We assessed methodologic quality and validity of studies without consideration of the results. The review authors independently extracted data and performed meta‐analyses using risk ratios (RR) and risk differences (RD) for dichotomous data and mean difference for continuous data with 95% confidence intervals (CI). For significant results, we calculated the number needed to treat for an additional beneficial outcome (NNTB) or for an additional harmful outcome (NNTH). </p> </section> <section id="CD001240-sec-0006"> <h3 class="title" id="CD001240-sec-0006">Main results</h3> <p>In this updated review, we identified nine RCTs of any barbiturate therapy in term and late preterm infants aged less than three days old with perinatal asphyxia without evidence of seizures. Eight of these studies compared prophylactic barbiturate therapy to conventional treatment (enrolling 439 infants) and one study compared barbiturate therapy to treatment with phenytoin (enrolling 17 infants). </p> <p><b>Prophylactic barbiturate therapy versus conventional treatment:</b> one small trial reported a decreased risk of death or severe neurodevelopmental disability for barbiturate therapy (phenobarbital) versus conventional treatment (RR 0.33, 95% CI 0.14 to 0.78; RD ‐0.55, 95% CI ‐0.84 to ‐0.25; NNTB 2, 95% CI 1 to 4; 1 study, 31 infants) (very low quality evidence). </p> <p>Eight trials comparing prophylactic barbiturate therapy with conventional treatment following perinatal asphyxia demonstrated no significant impact on the risk of death (typical RR 0.88, 95% CI 0.55 to 1.42; typical RD ‐0.02, 95% CI ‐0.08 to 0.05; 8 trials, 429 infants) (low quality evidence) and the one small trial noted above reported a significant decrease in the risk of severe neurodevelopmental disability (RR 0.24, 95% CI 0.06 to 0.92; RD ‐0.43, 95% CI ‐0.73 to ‐0.13; NNTB 2, 95% CI 1 to 8; 1 study, 31 infants) (very low quality evidence). </p> <p>A meta‐analysis of the six trials reporting on seizures in the neonatal period demonstrated a statistically significant reduction in seizures in the prophylactic barbiturate group versus conventional treatment (typical RR 0.62, 95% CI 0.48 to 0.81; typical RD ‐0.18, 95% CI ‐0.27 to ‐0.09; NNTB 5, 95% CI 4 to 11; 6 studies, 319 infants) (low quality evidence). There were similar results in subgroup analyses based on type of barbiturate and Sarnat score. </p> <p><b>Prophylactic barbiturate therapy versus other prophylactic anticonvulsant therapy:</b> one study reported on prophylactic barbiturate versus prophylactic phenytoin. There was no significant difference in seizure activity in the neonatal period between the two study groups (RR 0.89, 95% CI 0.07 to 12.00; 1 trial, 17 infants). </p> </section> <section id="CD001240-sec-0007"> <h3 class="title" id="CD001240-sec-0007">Authors' conclusions</h3> <p>We found only low or very low quality evidence addressing the use of prophylactic barbiturates in infants with perinatal asphyxia. Although the administration of prophylactic barbiturate therapy to infants following perinatal asphyxia did reduce the risk of seizures, there was no reduction seen in mortality and there were few data addressing long‐term outcomes. The administration of prophylactic barbiturate therapy for late preterm and term infants in the immediate period following perinatal asphyxia cannot be recommended for routine clinical practice. If used at all, barbiturates should be reserved for the treatment of seizures. The results of the current review support the use of prophylactic barbiturate therapy as a promising area of research. Future studies should be of sufficient size and duration to detect clinically important reductions in mortality and severe neurodevelopmental disability and should be conducted in the context of the current standard of care, including the use of therapeutic hypothermia. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001240-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001240-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001240-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001240-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD001240-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001240-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD001240-abs-0004">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001240-abs-0003" lang="en"> <h3>Use of prophylactic barbiturates to prevent death or serious developmental problems in term or late preterm infants following birth asphyxia </h3> <p><b>Review question</b> </p> <p>Does the use of prophylactic barbiturate therapy reduce the possibility of dying or having severe developmental problems in term and late preterm infants following birth asphyxia? </p> <p><b>Background</b> </p> <p>Seizures (fits) are common following birth asphyxia (where the infant did not get enough oxygen during birth). These seizures may worsen brain injury caused by birth asphyxia. In theory, treatment with barbiturates (a medicine that causes relaxation and sleepiness and is used to treat seizures) given to babies soon after birth asphyxia may improve outcomes by preventing seizures and protecting the brain. Such treatment is called prophylaxis because it is given to prevent seizures rather than treat them once they have happened. Barbiturate therapy has some side effects and there are concerns that barbiturates might impair brain development. </p> <p><b>Study characteristics</b> </p> <p>We identified nine clinical trials for inclusion in this review by searching medical databases in November 2015. We found only low or very low quality evidence of prophylactic barbiturates in infants with perinatal asphyxia. The studies in this review included small numbers of babies and only a few studies looked at the health of infants over a long period of time. </p> <p><b>Key results</b> </p> <p>At present, there is not enough information to recommend giving barbiturate therapy to newborn babies soon after birth asphyxia but before seizures start. </p> <p><b>Conclusion</b> </p> <p>It is unclear whether giving barbiturates to newborn babies soon after birth asphyxia but before seizures start is safe or effective. More studies are needed. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001240-sec-0088" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001240-sec-0088"></div> <h3 class="title" id="CD001240-sec-0089">Implications for practice</h3> <section id="CD001240-sec-0089"> <p>Although the administration of prophylactic barbiturate therapy to infants following perinatal asphyxia did reduce the risk of seizures, there was no reduction in mortality and there remains a paucity of data for long‐term outcomes. At the present time, the administration of prophylactic barbiturate therapy to late preterm and term infants in the immediate period following perinatal asphyxia cannot be recommended for routine clinical practice. </p> </section> <h3 class="title" id="CD001240-sec-0090">Implications for research</h3> <section id="CD001240-sec-0090"> <p>Given the frequent use of phenobarbital in this population, trials of prophylactic barbiturate therapy remain an important area for further investigation. Future trials should be of high quality, randomized controlled trials with blinding of allocation, performance, and outcome assessment. These studies should be sufficient size to detect clinically important reductions in mortality and severe neurodevelopmental disability and should be conducted in the context of therapeutic hypothermia, as there is currently no data for infants in this setting. The next generation of studies should use 'state of the art' diagnosis and management of seizures in neonates, including either use of amplitude‐integrated electroencephalography or continuous video monitoring electroencephalography in the management of these high risk infants. </p> <p>Potential adverse effects, such as hypotension and respiratory depression following barbiturate therapy, should be prospectively defined and reported. Given the relatively low incidence of perinatal asphyxia, future studies should include a collaborative effort between centers. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001240-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001240-sec-0015"></div> <div class="table" id="CD001240-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Barbiturate treatment compared to placebo or no treatment</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Barbiturate treatment compared to placebo or no treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> infants with perinatal asphyxia<br/> <b>Setting:</b> neonatal intensive care<br/> <b>Intervention:</b> prophylactic barbiturate<br/> <b>Comparison:</b> no treatment or selective barbiturate treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with selective barbiturate treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with prophylactic barbiturate</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death or major neurodevelopmental disability<br/> follow‐up: &gt; 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.33<br/> (0.14 to 0.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>31<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Very low quality</p> <p><sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Risk of bias: unblinded study; concern regarding performance bias, detection bias, and incomplete follow‐up. Imprecision: 95% CI were wide and imprecise </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>813 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>268 per 1000<br/> (114 to 634) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/> (0.55 to 1.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>429<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low quality</p> <p><sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Risk of bias: unblinded studies; concern regarding performance bias and detection bias. Imprecision: 95% CI were wide and imprecise </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>145 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>128 per 1000<br/> (80 to 206) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major neurodevelopmental disability<br/> follow‐up: &gt; 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.24<br/> (0.06 to 0.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>31<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Very low quality</p> <p><sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Risk of bias: unblinded study; concern regarding performance bias, detection bias, and incomplete follow‐up. Imprecision: 95% CI were wide and imprecise </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>563 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>135 per 1000<br/> (34 to 518) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cerebral palsy</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.58<br/> (0.19 to 1.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>69<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Very low quality</p> <p><sup>1, 2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Risk of bias: unblinded studies; concern regarding performance bias and detection bias. Imprecision: 95% CI were wide and imprecise. Inconsistency: clinically important heterogeneity noted </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>242 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>141 per 1000<br/> (46 to 412) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Developmental delay</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.54<br/> (0.24 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>63<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Very low quality</p> <p><sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Risk of bias: unblinded studies; concern regarding performance bias and detection bias. Imprecision: 95% CI were wide and imprecise </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>355 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>192 per 1000<br/> (85 to 422) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Seizures (clinical or electrographic)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.62<br/> (0.48 to 0.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>319<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low quality</p> <p><sup>1, 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Risk of bias: unblinded studies; concern regarding performance bias and detection bias. Inconsistency: statistical heterogeneity noted </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>474 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>294 per 1000<br/> (228 to 384) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Abnormal neurologic exam at discharge</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.85<br/> (0.67 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>245<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low quality</p> <p><sup>1, 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Risk of bias: unblinded studies; concern regarding performance bias and detection bias. Inconsistency: statistical heterogeneity noted </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>432 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>367 per 1000<br/> (290 to 467) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded for possible performance and detection bias. </p> <p><sup>2</sup> Imprecision: wide CIs. Sample size below optimal information size. </p> <p><sup>3</sup> Clinically important heterogeneity noted. </p> <p><sup>4</sup> I<sup>2</sup> = 68%. </p> <p><sup>5</sup> I<sup>2</sup> = 76%. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001240-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001240-sec-0016"></div> <p>Seizures are common following perinatal asphyxia and may exacerbate secondary neuronal injury. Barbiturate therapy has been used for infants with perinatal asphyxia in order to prevent seizures. However, barbiturate therapy may adversely affect neurodevelopment leading to concern regarding aggressive use in neonates. </p> <section id="CD001240-sec-0017"> <h3 class="title" id="CD001240-sec-0017">Description of the condition</h3> <p>Perinatal asphyxia resulting in hypoxic‐ischemic encephalopathy (HIE) remains an important cause of mortality and severe long‐term neurologic and developmental disability in children worldwide. </p> <p>Paramount in the treatment of HIE is the early identification of infants whose encephalopathy may be subject to treatment. The management of these infants has traditionally been supportive, with the goal of restoring and maintaining cerebral perfusion, maintaining glucose homeostasis, treating other organ dysfunction, and treating seizures when present. Currently, there are no targeted neuroprotective interventions that have been shown to be effective in human trials, with the notable exception of therapeutic hypothermia (<a href="./references#CD001240-bbs2-0035" title="JacobsSE , BergM , HuntR , Tarnow‐MordiWO , InderTE , DavisPG . Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD003311.pub3; PUBMED: 23440789] ">Jacobs 2013</a>). Multiple trials have shown that initiation of therapeutic hypothermia, both whole body and selective head cooling, within six hours of age reduces mortality without increasing major morbidity in survivors (<a href="./references#CD001240-bbs2-0035" title="JacobsSE , BergM , HuntR , Tarnow‐MordiWO , InderTE , DavisPG . Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD003311.pub3; PUBMED: 23440789] ">Jacobs 2013</a>). Although there are multiple etiologies for neonatal encephalopathy, the use of therapeutic hypothermia is restricted to infants with HIE due to perinatal asphyxia. Typically, the highest risk infants are able to be identified shortly after birth by a constellation of clinical findings including: </p> <p> <ul id="CD001240-list-0001"> <li> <p>evidence of a sentinel event during labor (i.e. fetal heart rate abnormality);</p> </li> <li> <p>a severely depressed infant (low extended Apgar score);</p> </li> <li> <p>the need for resuscitation in the delivery room (i.e. intubation, chest compressions with or without epinephrine); </p> </li> <li> <p>evidence of severe fetal acidemia (cord umbilical artery pH less than 7.00 or base deficit greater than 16 mEq/L (16 mmol/L), or both); </p> </li> <li> <p>evidence of an early abnormal neurologic examination or abnormal assessment of cerebral function, or both (<a href="./references#CD001240-bbs2-0043" title="PerlmanJM , RisserR . Can asphyxiated infants at risk for neonatal seizures be rapidly identified by current high‐risk markers?. Pediatrics1996;97(4):456‐62. [PUBMED: 8632928] ">Perlman 1996</a>; <a href="./references#CD001240-bbs2-0044" title="PerlmanJM . Summary proceedings from the neurology group on hypoxic‐ischemic encephalopathy. Pediatrics2006; Vol. 117, issue 3 Pt 2:S28‐33. [PUBMED: 16777819] ">Perlman 2006</a>). </p> </li> </ul> </p> <p>The therapeutic window that exists to minimize secondary injury and improve overall outcome is short (thought to be less than six hours) (<a href="./references#CD001240-bbs2-0025" title="GunnAJ , GunnTR , GunningMI , WilliamsCE , GluckmanPD . Neuroprotection with prolonged head cooling started before postischemic seizures in fetal sheep. Pediatrics1998;102(5):1098‐106. [PUBMED: 9794940] ">Gunn 1998</a>). Following a reversible hypoxic‐ischemic insult, neuronal cell death occurs in two phases (<a href="./references#CD001240-bbs2-0022" title="GluckmanPD , WilliamsCE . When and why do brain cells die?. Developmental Medicine and Child Neurology1992;34(11):1010‐4. [PUBMED: 1358734] ">Gluckman 1992</a>; <a href="./references#CD001240-bbs2-0037" title="LorekA , TakeiY , CadyEB , WyattJS , PenriceJ , EdwardsAD , et al. Delayed (+ACI‐secondary+ACI‐) cerebral energy failure after acute hypoxia‐ischemia in the newborn piglet: continuous 48‐hour studies by phosphorus magnetic resonance spectroscopy. Pediatric Research1994;36(6):699‐706. [PUBMED: 7898977] ">Lorek 1994</a>; <a href="./references#CD001240-bbs2-0042" title="PenriceJ , CadyEB , LorekA , WylezinskaM , AmessPN , AldridgeRF , et al. Proton magnetic resonance spectroscopy of the brain in normal preterm and term infants, and early changes after perinatal hypoxia‐ischemia. Pediatric Research1996;40(1):6‐14. [PUBMED: 8798238] ">Penrice 1996</a>). Phase one, the initial anoxic event, results in primary neuronal injury and cell death due to cellular hypoxia with exhaustion of cellular energy stores (<a href="./references#CD001240-bbs2-0034" title="HossmanKA . Neuronal survival and revival during and after cerebral ischaemia. American Journal of Emergency Medicine1983;1(2):191‐7. [PUBMED: 6680620] ">Hossman 1983</a>). Phase two, the reperfusion phase, occurs following a latent period and results in delayed neuronal injury during the recovery period following initial resuscitation (<a href="./references#CD001240-bbs2-0057" title="WilliamsCE , GunnA , GluckmanPD . Time course of intracellular edema and epileptiform activity following prenatal cerebral ischemia in sheep. Stroke1991;22(4):516‐21. [PUBMED: 2024281] ">Williams 1991</a>). Mechanisms thought to be important in the second phase of neuronal injury include production of oxygen free radicals (<a href="./references#CD001240-bbs2-0039" title="McCordJM . Oxygen‐derived free radicals in postischemic tissue injury. New England Journal of Medicine1985;312(3):159‐63. [PUBMED: 2981404] ">McCord 1985</a>), intracellular calcium influx (<a href="./references#CD001240-bbs2-0056" title="SiesjoBK . Pathophysiology and treatment of focal cerebral ischaemia. Part II: Mechanisms of damage and treatment. Journal of Neurosurgery1992;77(3):337‐54. [PUBMED: 1506880] ">Siesjo 1992</a>), increase in excitatory neurotransmitters, cerebral edema, and active cell death or apoptosis (<a href="./references#CD001240-bbs2-0017" title="ButtkeTM , SandstromPA . Oxidative stress as a mediator of apoptosis. Immunology Today1994;15(1):7‐10. [PUBMED: 8136014] ">Buttke 1994</a>). Clinically, this second phase of injury is associated with encephalopathy and increased seizure activity. It is the severity of this second phase that correlates with mortality and adverse neurodevelopmental outcomes at one and four years of age (<a href="./references#CD001240-bbs2-0048" title="RothSC , EdwardsAD , CadyEB , DelpyDT , WyattJS , AzzopardiD , et al. Relation between cerebral oxidative metabolism following birth asphyxia, and neurodevelopmental outcome and brain growth at one year. Developmental Medicine and Child Neurology1992;34(4):285‐95. [PUBMED: 1572514] ">Roth 1992</a>; <a href="./references#CD001240-bbs2-0049" title="RothSC , BaudinJ , CadyE , JohalK , TownsendJP , WyattJS , et al. Relation of deranged neonatal cerebral oxidative metabolism with neurodevelopmental outcome and head circumference at 4 years. Developmental Medicine and Child Neurology1997;39(11):718‐25. [PUBMED: 9393884] ">Roth 1997</a>). </p> <p>A continuum of severity exists among infants with HIE. In an attempt to help estimate the risk of adverse outcomes, Sarnat and Sarnat developed the original scoring system for categorizing encephalopathy in infants after perinatal distress. This system, with some modifications, is the approach used by most authors/researchers today and includes Stage I (Sarnat 1) ‐ mild, Stage II (Sarnat 2) ‐ moderate, Stage III (Sarnat 3) ‐ severe (<a href="./references#CD001240-bbs2-0051" title="SarnatHB , SarnatMS . Neonatal encephalopathy following fetal distress. Archives of Neurology1976;33:696‐705. ">Sarnat 1976</a>). </p> </section> <section id="CD001240-sec-0018"> <h3 class="title" id="CD001240-sec-0018">Description of the intervention</h3> <p>Seizures are a common feature of HIE (<a href="./references#CD001240-bbs2-0051" title="SarnatHB , SarnatMS . Neonatal encephalopathy following fetal distress. Archives of Neurology1976;33:696‐705. ">Sarnat 1976</a>), occurring in up to 60% of infants with moderate to severe HIE (<a href="./references#CD001240-bbs2-0023" title="GluckmanPD , WyattJS , AzzopardiD , BallardR , EdwardsAD , FerrieroDM , et al. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. Lancet2005;365(9460):663‐70. [PUBMED: 15721471] ">Gluckman 2005</a>; <a href="./references#CD001240-bbs2-0045" title="PfisterRH , BinghamP , EdwardsEM , HorbarJD , KennyMJ , InderT , et al. The Vermont Oxford Neonatal Encephalopathy Registry: rational, methods, and initial results. BMC Pediatrics2012;12:84. [PUBMED: 22726296] ">Pfister 2012</a>; <a href="./references#CD001240-bbs2-0053" title="ShankaranS , LaptookAR , EhrenkranzRA , TysonJE , McDonaldSA , DonovanEF , et al. Whole‐body hypothermia for neonates with hypoxic‐ischemic encephalopathy. New England Journal of Medicine2005;353(15):1574‐84. [PUBMED: 16221780] ">Shankaran 2005</a>). When present, seizures substantially increase cerebral metabolic demand (<a href="./references#CD001240-bbs2-0063" title="YounkinDP , Delivoria‐PapadopoulosM , MarisJ , DonlonE , ClancyR , ChanceB . Cerebral metabolic effects of neonatal seizures measured with in vivo 31P NMR spectroscopy. Annals of Neurology1986;20(4):513‐9. [PUBMED: 3789667] ">Younkin 1986</a>), cause the release of excitatory neurotransmitters such as glutamate (<a href="./references#CD001240-bbs2-0040" title="McDonaldJW , JohnstonMV . Physiological and pathophysiological roles of excitatory amino acids during central nervous system development. Brain Research. Brain Research Reviews1990;15(1):41‐70. [PUBMED: 2163714] ">McDonald 1990</a>), lead to fluctuations in systemic arterial pressure (<a href="./references#CD001240-bbs2-0019" title="ClozelM , DavalJL , MoninP , DebrucC , MorselliPL , VertP . Regional cerebral blood flow during bicuculline‐induced seizures in the newborn piglet: effect of phenobarbital. Developmental Pharmacology and Therapeutics1985;8(3):189‐99. [PUBMED: 4006653] ">Clozel 1985</a>), and result in hypoxia and hypercapnia. Though the degree to which seizures are associated with an increased risk of death and neurodevelopmental disability in this population is unclear (<a href="./references#CD001240-bbs2-0021" title="GlassHC , GliddenD , JeremyRJ , BarkovichAJ , FerrieroDM , MillerSP . Clinical neonatal seizures are independently associated with outcome in infants at risk for hypoxic‐ischemic brain injury. Journal of Pediatrics2009;155(3):318‐23. [PUBMED: 19540512] ">Glass 2009</a>; <a href="./references#CD001240-bbs2-0036" title="KwonJM , GuilletR , ShankaranS , LaptookAR , McDonaldSA , EhrenkranzRA , et al. Clinical seizures in neonatal hypoxic‐ischemic encephalopathy have no independent impact on neurodevelopmental outcome: secondary analyses of data from the neonatal research network hypothermia trial. Journal of Child Neurology2011;26(3):322‐8. ">Kwon 2011</a>; <a href="./references#CD001240-bbs2-0038" title="McBrideMC , LaroiaN , GuilletR . Electrographic seizures in neonates correlate with poor neurodevelopmental outcome. Neurology2000;55(4):506‐13. [PUBMED: 10953181] ">McBride 2000</a>; <a href="./references#CD001240-bbs2-0060" title="WyattJS , GluckmanPD , LiuPY , AzzopardiD , BallardRA , EdwardsAD , et al. Determinants of outcomes after head cooling for neonatal encephalopathy. Pediatrics2007;119(5):912‐21. [PUBMED: 17473091] ">Wyatt 2007</a>), seizures are thought to contribute to ongoing neuronal injury following asphyxia (<a href="./references#CD001240-bbs2-0058" title="WirrellEC , ArmstrongEA , OsmanLD , YagerJY . Prolonged seizures exacerbate perinatal hypoxic‐ischemic brain damage. Pediatric Research2001;50(4):445‐54. [PUBMED: 11568286] ">Wirrell 2001</a>; <a href="./references#CD001240-bbs2-0061" title="YagerJY , ArmstrongEA , MiyashitaH , WirrellEC . Prolonged neonatal seizures exacerbate hypoxic‐ischemic brain damage: correlation with cerebral energy metabolism and excitatory amino acid release. Developmental Neuroscience2002;24(5):367‐81. [PUBMED: 12640175] ">Yager 2002</a>). The potential benefits of preventing further neuronal injury through the treatment and prevention of seizures following asphyxia has prompted the widespread use of anticonvulsants in this population. Barbiturates, specifically phenobarbital, remain the preferred drugs of choice for the management of neonatal seizures, including seizures that occur following perinatal asphyxia. </p> </section> <section id="CD001240-sec-0019"> <h3 class="title" id="CD001240-sec-0019">How the intervention might work</h3> <p>Barbiturates are a class of anticonvulsants that facilitate gamma‐aminobutyric acid (GABA)‐mediated opening of chloride channels and in so doing enhance the effectiveness of GABA. The anticonvulsant effect of barbiturates is seen when GABA activation of the postsynaptic GABA<sub>A</sub> receptor results in an influx of chloride, and thereby an inhibitory effect as seen in mature neurons. However, this effect is less consistent in the developing brain (<a href="./references#CD001240-bbs2-0018" title="CherubiniE , GaiarsaJL , Ben‐AriY . GABA: an excitatory transmitter in early postnatal life. Trends in Neurosciences1991;14(12):515‐9. [PUBMED: 1726341] ">Cherubini 1991</a>; <a href="./references#CD001240-bbs2-0047" title="RiveraC , VoipioJ , PayneJA , RuusuvuoriE . The K+/Cl‐ co‐transporter KCC2 renders GABA hyperpolarizing during neuronal maturation. Nature1999;397(6716):251‐5. [PUBMED: 9930699] ">Rivera 1999</a>; <a href="./references#CD001240-bbs2-0062" title="YamadaJ , OkabeA , ToyodaH , KilbW , LuhmannHJ , FukudaA . Cl‐ uptake promoting depolarizing GABA actions in immature rat neocortical neurones is mediated by NKCC1. Journal of Physiology2004;557(Pt 3):829‐41. [PUBMED: 15090604] ">Yamada 2004</a>). In addition to the potential anticonvulsant effects, barbiturates are also known to decrease central nervous system (CNS) metabolic rate when given in high doses (<a href="./references#CD001240-bbs2-0041" title="NilssonL . The influence of barbiturate anaesthesia upon the energy state and upon acid‐base parameters of the brain in arterial hypotension and in asphyxia. Acta Neurologica Scandinavica1971;47(2):233‐53. [PUBMED: 5566570] ">Nilsson 1971</a>), reduce calcium entry postischemia, and scavenge free radicals (<a href="./references#CD001240-bbs2-0020" title="DemopoulosHG , FlammES , SeligmanMC , JorgensenE , RansohoffJ . Antioxidant effects of barbiturates in model membranes undergoing free radical damage. Acta Neurologica Scandinavica1977;64:152‐3. [PUBMED: 268766] ">Demopoulos 1977</a>). Thus, barbiturates may theoretically attenuate the cascade of damaging processes initiated by the hypoxic‐ischemic insult and reduce secondary neuronal injury. For these reasons, many clinicians have used barbiturates, specifically phenobarbital, prophylactically with or without therapeutic hypothermia, in cases of HIE. While there are data to suggest that seizure duration and evidence of brain injury on magnetic resonance imaging (MRI) may be reduced when either clinical or subclinical seizure patterns are treated (<a href="./references#CD001240-bbs2-0013" title="vanRooijLG , ToetMC , vanHuffelenAC , GroenendaalF , LaanW , ZecicA , et al. Effect of treatment of subclinical neonatal seizures detected with aEEG: randomized, controlled trial. Pediatrics2010;125(2):e358‐66. [PUBMED: 20100767] ">van Rooij 2010</a>), animal models in the developing brain have been conflicting, demonstrating abnormal neuronal development both following phenobarbital exposure (<a href="./references#CD001240-bbs2-0016" title="BittigauP , SifringerM , GenzK , ReithE , PospischilD , GovindarajaluS , et al. Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proceedings of the National Academy of Sciences of the United States of America2002;99(23):15089‐94. [PUBMED: 12417760] ">Bittigau 2002</a>) and seizures (<a href="./references#CD001240-bbs2-0033" title="HolmesGL , Ben‐AriY . Seizures in the developing brain: perhaps not so benign after all. Neuron1998;21(6):1231‐4. [PUBMED: 9883716] ">Holmes 1998</a>). </p> </section> <section id="CD001240-sec-0020"> <h3 class="title" id="CD001240-sec-0020">Why it is important to do this review</h3> <p>Although therapeutic hypothermia has led to improvement in outcomes for infants with HIE, there remains a significant degree of morbidity and mortality among these infants. The establishment of safe and effective adjunct therapies is important to provide further neuroprotection and improve neurodevelopmental outcomes in this population. While the theoretical benefits of prophylactic phenobarbital administration seem to support its use, the potential risks associated with such use cannot be overlooked. These risks include, potential fluctuations in systemic blood pressure, mainly hypotension following administration, and the potential negative cognitive developmental effects suggested by animal studies. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001240-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001240-sec-0021"></div> <p>To determine the effect of administering prophylactic barbiturate therapy on death or neurodevelopmental disability in term and late preterm infants following perinatal asphyxia. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001240-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001240-sec-0022"></div> <section id="CD001240-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001240-sec-0024"> <h4 class="title">Types of studies</h4> <p>All published or unpublished randomized controlled trials (RCTs) or quasi‐RCTs of prophylactic barbiturate use in asphyxiated late preterm and term infants. </p> </section> <section id="CD001240-sec-0025"> <h4 class="title">Types of participants</h4> <p> <ul id="CD001240-list-0002"> <li> <p>Term infants (37 weeks or greater) and late preterm infants (34 to 36+6 weeks' gestation) three days of age or less with perinatal asphyxia. </p> </li> <li> <p>Evidence of perinatal asphyxia, characterized by evidence of neonatal or fetal distress with each enrolled infant satisfying at least one of the following criteria: </p> <ul id="CD001240-list-0003"> <li> <p>Cord gas or postnatal blood gas (within the first hour of life) with pH 7.0 or less or base deficit 12 mEq/L or greater; </p> </li> <li> <p>Apgar score 5 or less at 10 minutes;</p> </li> <li> <p>Need for mechanical ventilation or resuscitation at 10 minutes of life;</p> </li> <li> <p>with or without evidence of encephalopathy (moderate or severe) according to Sarnat staging (<a href="./references#CD001240-bbs2-0051" title="SarnatHB , SarnatMS . Neonatal encephalopathy following fetal distress. Archives of Neurology1976;33:696‐705. ">Sarnat 1976</a>): </p> <ul id="CD001240-list-0004"> <li> <p>Stage 1 (mild): hyperalertness, hyper‐reflexia, dilated pupils, tachycardia, absence of seizures; </p> </li> <li> <p>Stage 2 (moderate): lethargy, hyper‐reflexia, miosis, bradycardia, seizures, hypotonia with weak suck, and Moro; </p> </li> <li> <p>Stage 3 (severe): stupor, flaccidity, small‐to‐mid position pupils that react poorly to light, decreased stretch reflexes, hypothermia, and absent Moro. </p> </li> </ul> </li> </ul> </li> <li> <p>No evidence of seizures.</p> </li> <li> <p>No major congenital abnormalities recognizable at birth.</p> </li> </ul> </p> <p>Seizures were considered present if suspected clinically or identified electroencephalographically via electroencephalograph (EEG) or amplitude‐integrated electroencephalography (aEEG). </p> <p>(Modified from <a href="./references#CD001240-bbs2-0035" title="JacobsSE , BergM , HuntR , Tarnow‐MordiWO , InderTE , DavisPG . Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD003311.pub3; PUBMED: 23440789] ">Jacobs 2013</a>.) </p> </section> <section id="CD001240-sec-0026"> <h4 class="title">Types of interventions</h4> <p>Barbiturates administered in the early neonatal period (within the first three days of life) with the intention of preventing seizures or improving neurodevelopmental outcomes and mortality (or both) following perinatal asphyxia. </p> </section> <section id="CD001240-sec-0027"> <h4 class="title">Types of outcome measures</h4> <section id="CD001240-sec-0028"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD001240-list-0005"> <li> <p>Death or major neurodevelopmental disability assessed at 12 months of age or greater (defined as cerebral palsy, developmental delay (Bayley or Griffith assessment more than two standard deviations (SD) below the mean) or intellectual impairment (intelligence quotient (IQ) more than two SD below mean), blindness (vision less than 6/60 in both eyes) or sensorineural deafness requiring amplification). </p> </li> </ul> </p> </section> <section id="CD001240-sec-0029"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD001240-list-0006"> <li> <p>Death (at any time).</p> </li> <li> <p>Major neurodevelopmental disability assessed at 12 months of age or greater (defined as cerebral palsy, developmental delay (Bayley or Griffith assessment more than two SD below the mean) or intellectual impairment (intelligence quotient (IQ) more than two SD below mean), blindness (vision less than 6/60 in both eyes) or sensorineural deafness requiring amplification). </p> </li> <li> <p>Each component of major neurodevelopmental disability:</p> <ul id="CD001240-list-0007"> <li> <p>cerebral palsy;</p> </li> <li> <p>developmental delay:</p> <ul id="CD001240-list-0008"> <li> <p>Bayley or Griffith assessment more than two SD below the mean;</p> </li> <li> <p>Neuromotor development (Bayley Scales of Infant Development ‐ Psychomotor Development Index (BSID PDI)) assessed in survivors; </p> </li> <li> <p>Cognitive development (Bayley Scales of Infant Development ‐ Mental Development Index (BSID MDI)) assessed in survivors; </p> </li> </ul> </li> <li> <p>intellectual impairment (IQ more than two SD below mean);</p> </li> <li> <p>blindness (vision less than 6/60 in both eyes);</p> </li> <li> <p>sensorineural deafness requiring amplification.</p> </li> </ul> </li> <li> <p>Seizures (suspected clinically or identified by EEG or aEEG):</p> <ul id="CD001240-list-0009"> <li> <p>seizures during initial neonatal period;</p> </li> <li> <p>seizures or need for anticonvulsants at follow‐up 12 months of age or greater.</p> </li> </ul> </li> <li> <p>Incidence of adverse effects of barbiturate administration:</p> <ul id="CD001240-list-0010"> <li> <p>respiratory depression requiring intubation;</p> </li> <li> <p>hypotension requiring inotropic support;</p> </li> <li> <p>significant rash (i.e. exfoliative dermatitis, Stevens‐Johnson syndrome).</p> </li> </ul> </li> </ul> </p> <section id="CD001240-sec-0030"> <h6 class="title">Post hoc outcomes</h6> <p> <ul id="CD001240-list-0011"> <li> <p>Abnormal neurologic exam at discharge.</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD001240-sec-0031"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD001240-sec-0032"> <h4 class="title">Electronic searches</h4> <p><a href="./appendices#CD001240-sec-0094">Appendix 1</a> shows the original search strategy in 2007. </p> <p>For the 2015 update, we used the criteria and standard methods of Cochrane and the Cochrane Neonatal Review Group (see <a href="http://neonatal.cochrane.org/resources-review-authors" target="_blank">the Cochrane Neonatal Group search strategy for specialized register</a>). </p> <p>We conducted a comprehensive search including: Cochrane Central Register of Controlled Trials (CENTRAL, 2015, Issue 11); MEDLINE via PubMed (1996 to 30 November 2015); EMBASE (1980 to 30 November 2015); and CINAHL (1982 to 30 November 2015) using the following search terms: (phenobarbital OR anticonvulsant) AND (asphyxia OR encephalopathy), plus database‐specific limiters for RCTs and neonates (see <a href="./appendices#CD001240-sec-0097">Appendix 2</a> for the full search strategies for each database). We applied no language restrictions. </p> <p>We searched clinical trials registries for ongoing or recently completed trials (<a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>; the World Health Organization's International Trials Registry and Platform <a href="http://www.whoint/ictrp/search/en/" target="_blank">www.whoint/ictrp/search/en/</a>, and the <a href="http://www.isrctn.com/" target="_blank">ISRCTN Registry</a>). </p> </section> <section id="CD001240-sec-0033"> <h4 class="title">Searching other resources</h4> <p>Published abstracts: we handsearched the abstracts of the Society for Pediatric Research (USA) (published in <i>Pediatric Research</i>) for the years 1985 to 1999 using the following key words: {phenobarbital, anticonvulsant} AND {asphyxia, encephalopathy}. We searched abstracts for 2000 to 2014 electronically through the Pediatric Academic Societies' <a href="http://www.abstracts2view.com/pasall/" target="_blank">website</a>. </p> </section> </section> <section id="CD001240-sec-0034"> <h3 class="title" id="CD001240-sec-0034">Data collection and analysis</h3> <section id="CD001240-sec-0035"> <h4 class="title">Selection of studies</h4> <p>The review authors (LY, MB, RS) screened the title and abstract of studies identified by the above search strategy. We reviewed the full‐text reports of each study identified as potentially relevant. We included studies meeting any of the prespecified inclusion criteria and evaluated them for inclusion and methodologic quality without consideration of results. Review authors were not blinded to authorship, institution, or journal. </p> </section> <section id="CD001240-sec-0036"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (LY, RS) separately extracted, assessed, and coded all data for each study using a form that was designed specifically for this review. For each included study, we collected information regarding the method of randomization, blinding, drug intervention, stratification, and whether the trial was conducted at a single center or multiple centers. We noted information regarding inclusion criteria, including gestational age, postnatal age at the time of treatment, and disease severity criteria. We collected information on clinical outcomes including death, neurodevelopmental disability assessed at 12 months of age or greater (defined as cerebral palsy, developmental delay or intellectual impairment, blindness (vision less than 6/60 in both eyes), or sensorineural deafness requiring amplification), seizure in the neonatal period, continued need for anticonvulsant therapy or persistent seizures at follow‐up 12 months of age or greater, hypotension requiring inotropic support, respiratory depression requiring intubation, and significant rash following administration of anticonvulsant. </p> <p>Seizures were either apparent clinically or detected by EEG or aEEG.</p> <p>For each study, one review author entered final data into Review Manager 5 and a second review author checked them (<a href="./references#CD001240-bbs2-0046" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). A third review author addressed any disagreements. </p> </section> <section id="CD001240-sec-0037"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used the standard method of the Cochrane Neonatal Review Group to assess risk of bias. The review authors independently assessed the risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001240-bbs2-0032" title="HigginsJPT , GreeneS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We resolved any disagreements by discussion.  </p> <p>We assessed methodologic quality of the studies using the following criteria.</p> <p> <ul id="CD001240-list-0012"> <li> <p>Sequence generation (checking for possible selection bias): for each included study, we categorized the method used to generate the allocation sequence as:  </p> <ul id="CD001240-list-0013"> <li> <p>adequate (any truly random process, e.g. random number table; computer random number generator);  </p> </li> <li> <p>inadequate (any nonrandom process, e.g. odd or even date of birth; hospital or clinic record number);  </p> </li> <li> <p>unclear.</p> </li> </ul> </li> <li> <p>Allocation concealment (checking for possible selection bias): for each included study, we categorized the method used to conceal the allocation sequence as:  </p> <ul id="CD001240-list-0014"> <li> <p>adequate (e.g. telephone or central randomization; consecutively numbered sealed opaque envelopes);  </p> </li> <li> <p>inadequate (open random allocation; unsealed or nonopaque envelopes, alternation; date of birth);  </p> </li> <li> <p>unclear.</p> </li> </ul> </li> <li> <p>Blinding (checking for possible performance bias): for each included study, we categorized the methods used to blind study participants and personnel from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes. We categorized the methods as:  </p> <ul id="CD001240-list-0015"> <li> <p>adequate, inadequate, or unclear for participants; </p> </li> <li> <p>adequate, inadequate, or unclear for personnel; </p> </li> <li> <p>adequate, inadequate, or unclear for outcome assessors. </p> </li> </ul> </li> <li> <p>Incomplete outcome data (checking for possible attrition bias through withdrawals, drop‐outs, protocol deviations): for each included study and for each outcome, we described the completeness of data including attrition and exclusions from the analysis. We noted whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared with the total randomized participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported or supplied by the trial authors, we re‐included missing data in the analyses. We categorized the methods as:  </p> <ul id="CD001240-list-0016"> <li> <p>adequate (less than 20% missing data);</p> </li> <li> <p>inadequate (20% or greater missing data);</p> </li> <li> <p>unclear.</p> </li> </ul> </li> <li> <p>Selective reporting bias: for each included study, we described how we investigated the possibility of selective outcome reporting bias and what we found. We assessed the methods as:  </p> <ul id="CD001240-list-0017"> <li> <p>adequate (where it was clear that all of the study's prespecified outcomes and all expected outcomes of interest to the review were reported);  </p> </li> <li> <p>inadequate (where not all the study's prespecified outcomes were reported; one or more reported primary outcomes were not prespecified; outcomes of interest were reported incompletely and so could not be used; study did not include results of a key outcome that would have been expected to have been reported); </p> </li> <li> <p>unclear.</p> </li> </ul> </li> <li> <p>Other sources of bias: for each included study, we described any important concerns we had about other possible sources of bias (e.g. whether there was a potential source of bias related to the specific study design or whether the trial was stopped early due to some data‐dependent process). We assessed whether each study was free of other problems that could put it at risk of bias as: yes; no; unclear. </p> </li> </ul> </p> </section> <section id="CD001240-sec-0038"> <h4 class="title">Measures of treatment effect</h4> <p>We examined the treatment effects of individual trials by comparing groups allocated to the treatment under study (prophylactic barbiturate therapy) versus placebo with conventional treatment (including anticonvulsants for the treatment of seizures) or conventional treatment alone. We compared data relating to the primary and secondary outcomes (<a href="#CD001240-sec-0028">Primary outcomes</a>; <a href="#CD001240-sec-0029">Secondary outcomes</a>). Where relevant and if possible, we calculated risk ratio (RR) and risk difference (RD) for dichotomous data and mean difference (MD) for continuous data, with 95% confidence intervals (CI) for all analyses. For significant results, we calculated the number needed to treat for an additional beneficial outcome (NNTB) or additional harmful outcome (NNTH). Analysis of outcome data was by intention to treat. </p> </section> <section id="CD001240-sec-0039"> <h4 class="title">Assessment of heterogeneity</h4> <p>We examined treatment effects of individual trials and heterogeneity between trials by inspecting the forest plots and quantifying the impact of heterogeneity using the I<sup>2</sup> statistic. If we detected statistical heterogeneity, we planned to explore the possible causes (e.g. differences in study quality, participants, intervention regimens, or outcome assessments) using post hoc subgroup analyses. </p> </section> <section id="CD001240-sec-0040"> <h4 class="title">Data synthesis</h4> <p>Where relevant, we performed meta‐analyses using the fixed‐effect 'assumption free' model. Where relevant and if possible, we examined heterogeneity between trial results using the I<sup>2</sup> test for dichotomous outcomes. </p> <section id="CD001240-sec-0041"> <h5 class="title">Quality of evidence</h5> <p>We assessed the quality of evidence for the main comparison at the outcome level using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (<a href="./references#CD001240-bbs2-0027" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383‐94. [PUBMED: 21195583] ">Guyatt 2011a</a>). This methodologic approach considers evidence from RCTs as high quality that may be downgraded based on consideration of any of five areas: design (risk of bias), consistency across studies, directness of the evidence, precision of estimates, and presence of publication bias (<a href="./references#CD001240-bbs2-0027" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383‐94. [PUBMED: 21195583] ">Guyatt 2011a</a>). The GRADE approach results in an assessment of the quality of a body of evidence in one of four grades: </p> <p> <ul id="CD001240-list-0018"> <li> <p>high: we are very confident that the true effect lies close to that of the estimate of the effect; </p> </li> <li> <p>moderate: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; </p> </li> <li> <p>low: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect; </p> </li> <li> <p>very low: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect (<a href="./references#CD001240-bbs2-0052" title="SchünemannH , BrożekJ , GuyattG , OxmanA (editors) . GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. Available from http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html. ">Schünemann 2013</a>). </p> </li> </ul> </p> <p>The review authors assessed the quality of the evidence found for outcomes identified as critical or important for clinical decision making. These outcomes were defined post hoc and included: death or major neurodevelopmental disability assessed at 12 months of age or greater (defined as cerebral palsy, developmental delay (Bayley or Griffith assessment more than two SD below the mean) or intellectual impairment (IQ more than two SD below mean), blindness (vision less than 6/60 in both eyes) or sensorineural deafness requiring amplification), as well as death (at any time), major neurodevelopmental disability assessed at 12 months of age or greater, and cerebral palsy or developmental delay. In addition, we included seizures (suspected clinically or identified by EEG or aEEG) and abnormal neurologic exam at discharge. </p> <p>In cases where we considered the risk of bias arising from inadequate concealment of allocation, randomized assignment, complete follow‐up, or blinded outcome assessment to reduce our confidence in the effect estimates, we downgraded the quality of evidence accordingly (<a href="./references#CD001240-bbs2-0028" title="GuyattGH , OxmanAD , VistG , KunzR , BrozekJ , Alonso‐CoelloP , et al. GRADE guidelines: 4. Rating the quality of evidence ‐ study limitations (risk of bias). Journal of Clinical Epidemiology2011;64(4):407‐15. [PUBMED: 21247734] ">Guyatt 2011b</a>). We evaluated consistency by similarity of point estimates, extent of overlap of CIs and statistical criteria including measurement of heterogeneity (I<sup>2</sup> statistic). We downgraded the quality of evidence when large and unexplained inconsistency across studies results was present (i.e. some studies suggested important benefit and other studies suggested no effect or harm without a clinical explanation) (<a href="./references#CD001240-bbs2-0029" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 7. Rating the quality of evidence ‐ inconsistency. Journal of Clinical Epidemiology2011;64(12):1294‐302. [PUBMED: 21803546] ">Guyatt 2011c</a>). We assessed precision according with the 95% CI around the pooled estimation (<a href="./references#CD001240-bbs2-0030" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence ‐ imprecision. Journal of Clinical Epidemiology2011;64(12):1283‐93. [PUBMED: 21839614] ">Guyatt 2011d</a>). When trials were conducted in populations other than the target population, we downgraded the quality of evidence because of indirectness (<a href="./references#CD001240-bbs2-0031" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 8. Rating the quality of evidence ‐ indirectness. Journal of Clinical Epidemiology2011;64(12):1303‐10. [PUBMED: 21802903] ">Guyatt 2011e</a>). </p> <p>We entered data (i.e. pooled estimates of the effects and corresponding 95% CI) and explicit judgments for each of the above aspects assessed into the Guideline Development Tool, the software used to create 'Summary of findings' tables (<a href="./references#CD001240-bbs2-0024" title="BrozekJ , OxmanA , SchünemannH . GRADEpro [Version 3.2 for Windows]. McMaster University, 2008. ">GRADEpro 2008</a>). We explained all judgments involving the assessment of the study characteristics described above in footnotes or comments in the 'Summary of findings' table. </p> </section> </section> <section id="CD001240-sec-0042"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD001240-sec-0043"> <h5 class="title">Barbiturate treatment compared to placebo or no treatment</h5> <p>Subgroup analyses:</p> <p> <ul id="CD001240-list-0019"> <li> <p>gestational age (late preterm (34 to 36+6 weeks' gestation) versus term (37 weeks' gestation or greater)); </p> </li> <li> <p>type of barbiturate (phenobarbital or thiopentone);</p> </li> <li> <p>severity of HIE (Sarnat score 2 or greater);</p> </li> <li> <p>cooling therapy;</p> </li> <li> <p>studies in low‐ and middle‐income countries.</p> </li> </ul> </p> </section> <section id="CD001240-sec-0044"> <h5 class="title">Barbiturate treatment compared to other barbiturate treatment</h5> <p>Subgroup analyses:</p> <p> <ul id="CD001240-list-0020"> <li> <p>gestational age (late preterm (34 to 36+6 weeks' gestation) versus term (37 weeks' gestation or greater)); </p> </li> <li> <p>type of barbiturate (phenobarbital or thiopentone);</p> </li> <li> <p>severity of HIE (Sarnat score 2 or greater);</p> </li> <li> <p>cooling therapy;</p> </li> <li> <p>studies in low‐ and middle‐income countries.</p> </li> </ul> </p> </section> <section id="CD001240-sec-0045"> <h5 class="title">Barbiturate treatment compared to other nonbarbiturate anticonvulsant treatment</h5> <p>Subgroup analyses:</p> <p> <ul id="CD001240-list-0021"> <li> <p>gestational age (late preterm (34 to 36+6 weeks' gestation) versus term (37 weeks' gestation or greater)); </p> </li> <li> <p>type of anticonvulsant;</p> </li> <li> <p>severity of HIE (Sarnat score 2 or greater);</p> </li> <li> <p>cooling therapy;</p> </li> <li> <p>studies in low‐ and middle‐income countries.</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001240-sec-0046" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001240-sec-0046"></div> <section id="CD001240-sec-0047"> <h3 class="title">Description of studies</h3> <p>The search identified 11 RCTs or quasi‐RCTs using neonatal barbiturate therapy following perinatal asphyxia, including eight previously identified studies (<a href="./references#CD001240-bbs2-0003" title="GoldbergRN , MoscosoP , BauerCR , BloomFL , CurlessRG , BurkeB , et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. Journal of Pediatrics1986;109(5):851‐6. [PUBMED: 3534201] ">Goldberg 1986</a>; <a href="./references#CD001240-bbs2-0004" title="HallRT , HallFK , DailyDK . High‐dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three‐year follow‐up. Journal of Pediatrics1998;132(2):345‐8. [PUBMED: 9506654] ">Hall 1998</a>; <a href="./references#CD001240-bbs2-0005" title="RuthV , KorkmanM , LiikanenA , PaetauR . High‐dose phenobarbitol treatment to prevent postasphyxial brain damage: a 6‐year follow up [abstract]. Pediatric Research1991;30:638. [DOI: 10.1203/00006450‐199112000‐00091] ">Ruth 1991</a>; <a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>; <a href="./references#CD001240-bbs2-0007" title="Vargas‐OrigelA , Espinosa‐GarciaJOG , Muniz‐QuezadaE , Vargas‐NietoMA , Aguilar‐GarciaG . Prevention of hypoxic‐ischemic encephalopathy with high‐dose, early phenobarbital therapy [Prevencion de la encefalopatia hipoxico‐isquemica mediante Fenobarbital en forma temprana y a dosis alta]. Gaceta Medica de Mexico2004;140(2):147‐53. [MEDLINE: 15162947] ">Vargas‐Origel 2004</a>; <a href="./references#CD001240-bbs2-0008" title="VelaF , DuranJA , ChungaF , SerranoJS , VallsA . Preventive treatment of convulsions in perinatal asphyxia [Tratamiento profilactico de convulsiones en asfixia perinatal]. Anales Espanoles de Pediatria1987;27(2):95‐9. [PUBMED: 3662273] ">Vela 1987</a>; <a href="./references#CD001240-bbs2-0011" title="RuthV , VirkolaK , PaetauR , RaivioKO . Early high‐dose phenobarbital treatment for prevention of hypoxic‐ischemic brain damage in very low birth weight infants. Journal of Pediatrics1988;112(1):81‐6. [PUBMED: 2447257] ">Ruth 1988</a>; <a href="./references#CD001240-bbs2-0014" title="RochefortMJ , WilkinsonAR . The safety and efficacy of alternative anticonvulsant regimes to control newborns seizures [abstract]. Early Human Development1989;19:218. WilkinsonAR , RochefortMJ . Phenytoin reduces frequency and duration of neonatal seizures in the newborn: a randomised trial of four anticonvulsants [abstract]. Pediatric Research1989;26:522. ">Wilkinson 1989</a>), and three new studies (<a href="./references#CD001240-bbs2-0001" title="AvasiloaieiA , DimitriuC , MoscaluM , PaduraruL , StamatinM . High‐dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatrics International2013;55(5):589‐93. [PUBMED: 23659666] ">Avasiloaiei 2013</a>; <a href="./references#CD001240-bbs2-0002" title="GathwalaG , MarwahA , GahlautV , MarwahP . Effect of high‐dose phenobarbital on oxidative stress in perinatal asphyxia: an open label randomized controlled trial. Indian Pediatrics2011;48(8):613‐7. [PUBMED: 21169640] ">Gathwala 2011</a>; <a href="./references#CD001240-bbs2-0009" title="VelaphiS , MokhachaneM , MphahleleR , Beckh‐ArnoldE . Effect of prophylactic phenobarbital on seizures, encephalopathy and mortality in neonates with perinatal asphyxia. South African Journal of Child Health2013;7(1):17‐21. ">Velaphi 2013</a>) (<a href="#CD001240-fig-0001">Figure 1</a>). Eight studies compared barbiturate treatment to placebo or no treatment (<a href="./references#CD001240-bbs2-0001" title="AvasiloaieiA , DimitriuC , MoscaluM , PaduraruL , StamatinM . High‐dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatrics International2013;55(5):589‐93. [PUBMED: 23659666] ">Avasiloaiei 2013</a>; <a href="./references#CD001240-bbs2-0002" title="GathwalaG , MarwahA , GahlautV , MarwahP . Effect of high‐dose phenobarbital on oxidative stress in perinatal asphyxia: an open label randomized controlled trial. Indian Pediatrics2011;48(8):613‐7. [PUBMED: 21169640] ">Gathwala 2011</a>; <a href="./references#CD001240-bbs2-0003" title="GoldbergRN , MoscosoP , BauerCR , BloomFL , CurlessRG , BurkeB , et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. Journal of Pediatrics1986;109(5):851‐6. [PUBMED: 3534201] ">Goldberg 1986</a>; <a href="./references#CD001240-bbs2-0004" title="HallRT , HallFK , DailyDK . High‐dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three‐year follow‐up. Journal of Pediatrics1998;132(2):345‐8. [PUBMED: 9506654] ">Hall 1998</a>; <a href="./references#CD001240-bbs2-0005" title="RuthV , KorkmanM , LiikanenA , PaetauR . High‐dose phenobarbitol treatment to prevent postasphyxial brain damage: a 6‐year follow up [abstract]. Pediatric Research1991;30:638. [DOI: 10.1203/00006450‐199112000‐00091] ">Ruth 1991</a>; <a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>; <a href="./references#CD001240-bbs2-0007" title="Vargas‐OrigelA , Espinosa‐GarciaJOG , Muniz‐QuezadaE , Vargas‐NietoMA , Aguilar‐GarciaG . Prevention of hypoxic‐ischemic encephalopathy with high‐dose, early phenobarbital therapy [Prevencion de la encefalopatia hipoxico‐isquemica mediante Fenobarbital en forma temprana y a dosis alta]. Gaceta Medica de Mexico2004;140(2):147‐53. [MEDLINE: 15162947] ">Vargas‐Origel 2004</a>; <a href="./references#CD001240-bbs2-0009" title="VelaphiS , MokhachaneM , MphahleleR , Beckh‐ArnoldE . Effect of prophylactic phenobarbital on seizures, encephalopathy and mortality in neonates with perinatal asphyxia. South African Journal of Child Health2013;7(1):17‐21. ">Velaphi 2013</a>). One study compared barbiturate treatment to other nonbarbiturate therapy (<a href="./references#CD001240-bbs2-0008" title="VelaF , DuranJA , ChungaF , SerranoJS , VallsA . Preventive treatment of convulsions in perinatal asphyxia [Tratamiento profilactico de convulsiones en asfixia perinatal]. Anales Espanoles de Pediatria1987;27(2):95‐9. [PUBMED: 3662273] ">Vela 1987</a>). No studies compared barbiturate treatment to other barbiturate. </p> <div class="figure" id="CD001240-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram: review update." data-id="CD001240-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_n/nCD001240-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram: review update.</p> </div> </div> </div> <p>We excluded two studies using barbiturate therapy in neonates following perinatal asphyxia (<a href="./references#CD001240-bbs2-0011" title="RuthV , VirkolaK , PaetauR , RaivioKO . Early high‐dose phenobarbital treatment for prevention of hypoxic‐ischemic brain damage in very low birth weight infants. Journal of Pediatrics1988;112(1):81‐6. [PUBMED: 2447257] ">Ruth 1988</a> included preterm, very low birth weight infants and <a href="./references#CD001240-bbs2-0014" title="RochefortMJ , WilkinsonAR . The safety and efficacy of alternative anticonvulsant regimes to control newborns seizures [abstract]. Early Human Development1989;19:218. WilkinsonAR , RochefortMJ . Phenytoin reduces frequency and duration of neonatal seizures in the newborn: a randomised trial of four anticonvulsants [abstract]. Pediatric Research1989;26:522. ">Wilkinson 1989</a> used anticonvulsants for treatment of seizures, not prophylaxis). In addition, we excluded one previously included study not identified through our search (<a href="./references#CD001240-bbs2-0010" title="KuzemkoJA , HartleyS . Treatment of cerebral irritation in the newborn: double‐blind trial with chloral hydrate and diazepam. Developmental Medicine and Child Neurology1972;14(6):740‐6. [PUBMED: 4566107] ">Kuzemko 1972</a>, as it did not evaluate barbiturate therapy). </p> <section id="CD001240-sec-0048"> <h4 class="title">Results of the search</h4> <p>We updated the search in May 2014. Nine studies met criteria for inclusion, including three new studies. </p> <p>We also identified additional data for a previously included study, <a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a> (from a 2005 publication of the same study population). </p> <section id="CD001240-sec-0049"> <h5 class="title">Included studies</h5> <p>The individual details for each study are noted below and in the <a href="./references#CD001240-sec-0111" title="">Characteristics of included studies</a> table. </p> <section id="CD001240-sec-0050"> <h6 class="title">Barbiturate treatment compared to placebo or no treatment</h6> <p>Eight studies compared barbiturate therapy to conventional therapy with or without placebo (<a href="./references#CD001240-bbs2-0001" title="AvasiloaieiA , DimitriuC , MoscaluM , PaduraruL , StamatinM . High‐dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatrics International2013;55(5):589‐93. [PUBMED: 23659666] ">Avasiloaiei 2013</a>; <a href="./references#CD001240-bbs2-0002" title="GathwalaG , MarwahA , GahlautV , MarwahP . Effect of high‐dose phenobarbital on oxidative stress in perinatal asphyxia: an open label randomized controlled trial. Indian Pediatrics2011;48(8):613‐7. [PUBMED: 21169640] ">Gathwala 2011</a>; <a href="./references#CD001240-bbs2-0003" title="GoldbergRN , MoscosoP , BauerCR , BloomFL , CurlessRG , BurkeB , et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. Journal of Pediatrics1986;109(5):851‐6. [PUBMED: 3534201] ">Goldberg 1986</a>; <a href="./references#CD001240-bbs2-0004" title="HallRT , HallFK , DailyDK . High‐dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three‐year follow‐up. Journal of Pediatrics1998;132(2):345‐8. [PUBMED: 9506654] ">Hall 1998</a>; <a href="./references#CD001240-bbs2-0005" title="RuthV , KorkmanM , LiikanenA , PaetauR . High‐dose phenobarbitol treatment to prevent postasphyxial brain damage: a 6‐year follow up [abstract]. Pediatric Research1991;30:638. [DOI: 10.1203/00006450‐199112000‐00091] ">Ruth 1991</a>; <a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>; <a href="./references#CD001240-bbs2-0007" title="Vargas‐OrigelA , Espinosa‐GarciaJOG , Muniz‐QuezadaE , Vargas‐NietoMA , Aguilar‐GarciaG . Prevention of hypoxic‐ischemic encephalopathy with high‐dose, early phenobarbital therapy [Prevencion de la encefalopatia hipoxico‐isquemica mediante Fenobarbital en forma temprana y a dosis alta]. Gaceta Medica de Mexico2004;140(2):147‐53. [MEDLINE: 15162947] ">Vargas‐Origel 2004</a>; <a href="./references#CD001240-bbs2-0009" title="VelaphiS , MokhachaneM , MphahleleR , Beckh‐ArnoldE . Effect of prophylactic phenobarbital on seizures, encephalopathy and mortality in neonates with perinatal asphyxia. South African Journal of Child Health2013;7(1):17‐21. ">Velaphi 2013</a>). </p> <p>Four studies recorded long‐term neurodevelopmental outcome assessed at 12 months of age or greater (<a href="./references#CD001240-bbs2-0001" title="AvasiloaieiA , DimitriuC , MoscaluM , PaduraruL , StamatinM . High‐dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatrics International2013;55(5):589‐93. [PUBMED: 23659666] ">Avasiloaiei 2013</a>; <a href="./references#CD001240-bbs2-0003" title="GoldbergRN , MoscosoP , BauerCR , BloomFL , CurlessRG , BurkeB , et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. Journal of Pediatrics1986;109(5):851‐6. [PUBMED: 3534201] ">Goldberg 1986</a>; <a href="./references#CD001240-bbs2-0004" title="HallRT , HallFK , DailyDK . High‐dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three‐year follow‐up. Journal of Pediatrics1998;132(2):345‐8. [PUBMED: 9506654] ">Hall 1998</a>; <a href="./references#CD001240-bbs2-0005" title="RuthV , KorkmanM , LiikanenA , PaetauR . High‐dose phenobarbitol treatment to prevent postasphyxial brain damage: a 6‐year follow up [abstract]. Pediatric Research1991;30:638. [DOI: 10.1203/00006450‐199112000‐00091] ">Ruth 1991</a>). The remaining studies reported only short‐term neonatal outcomes (death, seizures in the neonatal period, and abnormal neurologic status) (<a href="./references#CD001240-bbs2-0002" title="GathwalaG , MarwahA , GahlautV , MarwahP . Effect of high‐dose phenobarbital on oxidative stress in perinatal asphyxia: an open label randomized controlled trial. Indian Pediatrics2011;48(8):613‐7. [PUBMED: 21169640] ">Gathwala 2011</a>; <a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>; <a href="./references#CD001240-bbs2-0007" title="Vargas‐OrigelA , Espinosa‐GarciaJOG , Muniz‐QuezadaE , Vargas‐NietoMA , Aguilar‐GarciaG . Prevention of hypoxic‐ischemic encephalopathy with high‐dose, early phenobarbital therapy [Prevencion de la encefalopatia hipoxico‐isquemica mediante Fenobarbital en forma temprana y a dosis alta]. Gaceta Medica de Mexico2004;140(2):147‐53. [MEDLINE: 15162947] ">Vargas‐Origel 2004</a>; <a href="./references#CD001240-bbs2-0009" title="VelaphiS , MokhachaneM , MphahleleR , Beckh‐ArnoldE . Effect of prophylactic phenobarbital on seizures, encephalopathy and mortality in neonates with perinatal asphyxia. South African Journal of Child Health2013;7(1):17‐21. ">Velaphi 2013</a>). </p> <p><a href="./references#CD001240-bbs2-0003" title="GoldbergRN , MoscosoP , BauerCR , BloomFL , CurlessRG , BurkeB , et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. Journal of Pediatrics1986;109(5):851‐6. [PUBMED: 3534201] ">Goldberg 1986</a> reported seizure activity and developmental outcome at 12 months of age or greater for 32 severely asphyxiated term neonates with signs of HIE and requiring mechanical ventilation within the first hour of life (15 infants randomized to conventional therapy (control) and 17 infants randomized to prophylactic thiopental plus conventional therapy) in a single‐center RCT. Participants were term infants (37 weeks' gestation or greater) with severe perinatal asphyxia who had neurologic signs of HIE (decreased or absent response to noxious stimuli, seizure activity, or increased irritability) and required mechanical ventilation within first hour of life; plus two of the following three criteria: perinatal distress (abnormal fetal heart pattern or requiring prolonged neonatal resuscitation); Apgar score of 4 or less at five minutes; and base deficit 15 mEq/L or greater within first hour of life. Thirty‐two infants met the inclusion criteria and were randomized. The RCT excluded six infants prior to randomization for intractable hypotension, congenital intrauterine infection, complex congenital malformations, and maternal chorioamnionitis. </p> <p>The thiopental treatment group (17 infants) received conventional therapy plus thiopental loading dose (15 mg/kg intravenous (IV) over 30 minutes), followed by a constant infusion of thiopental (10 mg/kg/hour for 90 minutes, 5 mg/kg/hour for 60 minutes, 3 mg/kg/hour for eight hours, 1.5 mg/kg/hour for six hours and 0.75 mg/kg/hour for six hours). The conventional therapy group (15 infants) received fluid restriction, mechanical ventilation, and treatment with phenobarbital or phenytoin for clinical apparent seizure activity. The primary outcome measured was reduction of intracranial pressure to the normal range. Secondary outcomes were hypotension requiring inotropes, overall effect on neurologic outcome, seizure activity over first 72 hours of life, death, and long‐term neurodevelopmental outcome. Neurodevelopmental assessments were performed at three, six, nine, 12, 18, 24, and 36 months. Developmental outcome was measured using the Bayley scales of infant development (normal 84 or greater, questionable 68 to 83, abnormal 67 or less) through two years of age, after which Stanford‐Binet assessments were performed. </p> <p><a href="./references#CD001240-bbs2-0005" title="RuthV , KorkmanM , LiikanenA , PaetauR . High‐dose phenobarbitol treatment to prevent postasphyxial brain damage: a 6‐year follow up [abstract]. Pediatric Research1991;30:638. [DOI: 10.1203/00006450‐199112000‐00091] ">Ruth 1991</a> reported on death before neurodevelopmental assessment and neurodevelopmental outcome at six years of age for 38 term neonates with evidence of perinatal asphyxia (17 controls randomized to conventional therapy and 21 infants randomized to prophylactic phenobarbital therapy) in a single‐center RCT. Eligible infants were term (37 weeks' gestation or greater) with evidence of perinatal asphyxia (five‐minute Apgar score 3 or less or need for ventilator assistance beyond 30 minutes of life). Thirty‐eight infants met the inclusion criteria and were randomized. The phenobarbital treatment group (21 infants) received conventional therapy plus a phenobarbital loading dose (30 mg/kg IV) prior to four hours of age, followed by a second dose of phenobarbital (15 mg/kg) four hours after the initial dose. These infants then received 5 mg/kg/day for five days. The control group (17 infants) received conventional therapy. Measured outcomes included death before neurodevelopmental assessment and disability (stated as cerebral palsy). Six‐year follow‐up included cognitive assessment (Wechsler Intelligence Scale for Children ‐ revised (WISC‐r)), expressed as IQ; neuropsychological tests (copying design (Visual‐Motor Integration (VMI) test), attention and confrontation naming (Developmental NEuroPSYchological (NEPSY) assessment)), and quality of life scale. </p> <p><a href="./references#CD001240-bbs2-0004" title="HallRT , HallFK , DailyDK . High‐dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three‐year follow‐up. Journal of Pediatrics1998;132(2):345‐8. [PUBMED: 9506654] ">Hall 1998</a> reported on seizures in the newborn period, death before neurodevelopmental evaluation, neurologic outcome at three years and serum and cerebrospinal fluid (CSF) enzyme levels for 40 severely asphyxiated term and post term infants (20 controls randomized to conventional therapy and 20 infants randomized to prophylactic phenobarbital) in a single‐center RCT. Eligible infants were 37 weeks' gestation or greater with severe perinatal asphyxia (initial arterial pH 7 or less with base deficit 15 mEq/L or greater; five‐minute Apgar 3 or less; or failure to initiate spontaneous respirations at 10 minutes of life). Infants were excluded if they had any condition that was abnormal unrelated to asphyxia. Forty infants met inclusion criteria and were randomized. Thirty‐one infants (15 in the phenobarbital group and 16 in the conventional therapy group) completed the trial. Study failures included inability to obtain successful lumbar puncture, protocol violations, and infants lost to follow‐up. All infants were outborn and transferred to the neonatal intensive care unit within the first day of life. The phenobarbital treatment group (n = 20) received conventional therapy plus a single phenobarbital dose (40 mg/kg IV over 60 minutes) immediately following trial entry. The control group (n = 20) received conventional therapy. Conventional therapy for both groups included phenobarbital administration for the treatment of clinical seizures. This trial evaluated reduction in the incidence of clinical seizures as a primary outcome. Secondary outcomes included total lactate dehydrogenase (LDH), creatine kinase (CK) and the presence or absence of CK‐BB isoenzymes in CSF obtained day one and day two. Deaths before neurodevelopmental assessment and neurodevelopmental outcomes at three years of age were also evaluated. Neurodevelopmental assessments were completed at six, 12, 24, and 36 months of age using the Gessell, Bayley, or Stanford‐Binet tests. Adverse effects of phenobarbital administration were evaluated including hypotension and respiratory depression. </p> <p><a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a> reported on CSF levels of lipid peroxides, antioxidant enzymes, and serum levels of antioxidant vitamins in relation to adverse outcomes (death or abnormal neurologic exam at discharge) for 45 asphyxiated late preterm and term infants with evidence of HIE (abnormalities in tone or level of consciousness, or both) within the first six hours of life (20 controls randomized to conventional therapy and 25 infants randomized to prophylactic phenobarbital therapy). Singh and colleagues published a follow‐up report (Singh 2005, see <a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>), on adverse outcomes (death or neurologic abnormality at discharge) and secondary outcome variables including seizures, need for ventilation, and multiorgan dysfunction for the same 45 asphyxiated late preterm and term infants with evidence of HIE in this single‐center RCT. Eligible infants for this trial were 34 weeks' gestation or greater with perinatal asphyxia and showed evidence of HIE in the first six hours of life. Infants were included if, in the setting of a one‐minute Apgar score of 5 or less and evidence of fetal distress (fetal bradycardia, meconium‐stained amniotic fluid or arterial cord pH 7.15 or less), they developed abnormalities in tone or level of consciousness (or both) within the first six hours of life. Sixty infants met inclusion criteria and were randomized. Following randomization, 15 infants were excluded because of CSF findings suggestive of meningitis (one infant) or intracranial bleed/traumatic lumbar puncture (14 infants), leaving 45 infants (20 infants in the control group and 25 infants in the phenobarbital group). In addition, infants were excluded if they had major congenital malformations or if their mothers received phenobarbital during the last week prior to delivery. The phenobarbital group received conventional therapy plus phenobarbital (20 mg/kg IV over 20 minutes) within the first six hours of life. The control group received conventional therapy. Conventional therapy was as per unit protocol for management of HIE and included phenobarbital administration for seizures diagnosed clinical. Measured outcomes included primary outcome of death or abnormal neurologic exam at discharge (exam performed as described by Amiel‐Tison). Secondary outcomes included seizures, need for ventilation, and multiorgan dysfunction (Singh 2005, see <a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>). CSF levels of malondialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GPx), and plasma levels of vitamins A and E were also evaluated at 10 to 12 hours of life and evaluated in relation to adverse outcomes (death or abnormal neurologic exam at discharge) (<a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>). Cranial ultrasounds were also obtained on day one, day three and day seven. Neonatologists who were blinded to group allocation performed discharge neurologic exam and cranial ultrasounds. In addition, evidence of adverse effects of phenobarbital administration included hypotension, need for ventilation, presence myocardial dysfunction, and excessive sleepiness. </p> <p><a href="./references#CD001240-bbs2-0007" title="Vargas‐OrigelA , Espinosa‐GarciaJOG , Muniz‐QuezadaE , Vargas‐NietoMA , Aguilar‐GarciaG . Prevention of hypoxic‐ischemic encephalopathy with high‐dose, early phenobarbital therapy [Prevencion de la encefalopatia hipoxico‐isquemica mediante Fenobarbital en forma temprana y a dosis alta]. Gaceta Medica de Mexico2004;140(2):147‐53. [MEDLINE: 15162947] ">Vargas‐Origel 2004</a> reported the frequency of HIE (according to Sarnat classification), clinical seizure activity, short‐term neurologic abnormalities, postasphyxial nonbrain complications, and adverse effects associated with phenobarbital administration for 73 term and post‐term infants with perinatal asphyxia (36 controls randomized to conventional treatment and 37 infants randomized to prophylactic phenobarbital) in an RCT. Eligible infants were term and post‐term infants (37 weeks' gestation or greater) with perinatal asphyxia (cord or arterial pH 7.0 or less within 15 minutes of life plus one or more of the following, base deficit 15 mEq/L or greater, Apgar score 3 or less at five minutes of life, or no spontaneous respiration by 15 minutes of life). Infants were excluded if they died within the first 48 hours of life; had major congenital abnormalities, congenital infection, or trauma during delivery; or exposure to maternal medications that would result in neonatal depression. The phenobarbital group received conventional therapy plus a phenobarbital loading dose (40 mg/kg IV over 60 minutes) administered within the first hour of life. The control group received placebo and conventional therapy, including phenobarbital at standard dosing for clinically evident seizure activity. Short‐term neonatal outcomes including clinical seizure activity, neurologic status at discharge, and postasphyxia nonbrain complications (renal, respiratory, cardiovascular, gastrointestinal, and metabolic) were measured. HIE grading according to Sarnat classification was performed to estimate frequency and severity of HIE. </p> <p><a href="./references#CD001240-bbs2-0002" title="GathwalaG , MarwahA , GahlautV , MarwahP . Effect of high‐dose phenobarbital on oxidative stress in perinatal asphyxia: an open label randomized controlled trial. Indian Pediatrics2011;48(8):613‐7. [PUBMED: 21169640] ">Gathwala 2011</a> reported on levels of lipid peroxides and antioxidant enzymes in CSF, death, and neurologic outcome at one‐month follow‐up for 72 inborn term neonates with severe perinatal asphyxia (36 controls randomized to conventional therapy and 36 infants randomized to prophylactic phenobarbital) in a single‐center RCT. Eligible participants were term infants (37 weeks' gestation or greater) with severe perinatal asphyxia (cord blood pH less than 7 and Apgar score 5 or less at five minutes). Seventy‐two infants met the inclusion criteria and were randomized. Four infants were excluded prior to randomization for obvious congenital malformation. The phenobarbital treatment group received conventional therapy per unit protocol for HIE plus a phenobarbital loading dose (40 mg/kg IV infusion over 60 minutes) within the first two hours of life. Heart rate, oxygen saturation, respiration, and mean arterial pressure were monitored continuously during administration. The conventional therapy group received conventional therapy for HIE per unit protocol. Primary outcomes were CSF levels of lipid peroxides (MDA) and antioxidant enzymes (SOD and GPx) at 12 ± 2 hours of life. Additional outcomes included death, seizure activity, neurologic exam at discharge and neurologic outcome at one‐month follow‐up (based on neurologic exam, MRI, and electroencephalogram (EEG) results) were also evaluated. HIE staging was assessed for each infant according to Sarnat staging. Cranial ultrasounds were also obtained on day three and day seven of life. Adverse effects of phenobarbital administration were evaluated including hypotension and respiratory depression. </p> <p><a href="./references#CD001240-bbs2-0009" title="VelaphiS , MokhachaneM , MphahleleR , Beckh‐ArnoldE . Effect of prophylactic phenobarbital on seizures, encephalopathy and mortality in neonates with perinatal asphyxia. South African Journal of Child Health2013;7(1):17‐21. ">Velaphi 2013</a> reported on seizure activity, death, and neurologic outcome at hospital discharge for 94 term and late preterm infants with perinatal asphyxia (44 infants randomized to placebo plus conventional therapy and 50 infants randomized to prophylactic phenobarbital plus conventional therapy) in a single‐center RCT. Eligible infants were 34 weeks' gestation or greater or 2000 g or greater (or both) with evidence of perinatal asphyxia (base deficit greater than 16 mEq/L measured within one hour of life and Apgar score 6 or less at five minutes or requiring resuscitation for more than five minutes). Ninety‐four infants met the inclusion criteria and were randomized. Exclusion criteria included presence of congenital abnormalities, inability to randomize by six hours of life, or lack of spontaneous respirations within 20 minutes of life with or without bradycardia. The prophylactic phenobarbital group received conventional therapy plus phenobarbital loading dose (40 mg/kg IV infused over 60 minutes) within the first six hours of life. The control group received conventional therapy plus placebo (normal saline 1 mL/kg IV infused over 60 minutes) within the first six hours of life. Conventional therapy for both groups included regular monitoring of vital signs and administration of dextrose containing IV fluids and antibiotics. Clinical seizures were treated with phenytoin with or without clonazepam. If seizures persisted despite treatment with phenytoin and clonazepam, the code was broken and phenobarbital was administered if the infant had been in the control group. If the infant was in the phenobarbital group, a blood phenobarbital level was obtained and phenobarbital was administered if the level was below the therapeutic range. Measured outcomes included seizures, death, and neurologic outcome at discharge (improving or worsening HIE stage as compared to Sarnat stage at time of enrollment). Neonatal consultants uninvolved the care of the study infants performed neurologic exams according to Sarnat staging in all infants as 12 to 24 hours, two to three days, and five to seven days after birth and on discharge. In addition, possible adverse effects of phenobarbital administration were monitored for including hypotension and respiratory depression. </p> <p><a href="./references#CD001240-bbs2-0001" title="AvasiloaieiA , DimitriuC , MoscaluM , PaduraruL , StamatinM . High‐dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatrics International2013;55(5):589‐93. [PUBMED: 23659666] ">Avasiloaiei 2013</a> reported on red blood cell activity of antioxidant enzymes (SOD and GPx), total serum antioxidant status (TAS), lipid peroxidation (using MDA), mortality, seizures, neurologic abnormalities at greater than 72 hours of life and long‐term neurologic outcome at 12 months of age or greater for 67 term neonates with perinatal asphyxia (23 controls randomized to supportive care, 22 infants randomized to prophylactic phenobarbital, and 22 infants randomized to erythropoietin) in a single‐center RCT. Participants included term infants 37 weeks' gestation or greater with severe perinatal asphyxia. Infants were determined to have perinatal asphyxia when three of the four criteria of the American Academy of Pediatrics and the American College of Obstetricians and Gynecologists were met (umbilical artery blood pH less than 7.0, base deficit 12 mEq/L or greater, Apgar 3 or less at more than five minutes of life, neonatal neurologic sequelae (i.e. seizures, coma, hypotonia), multiple organ involvement (i.e. kidney, lungs, liver, heart, intestines), or a combination of these. Infants less than 37 weeks' gestation, with major congenital malformations, and with hemolytic disease due to rhesus (Rh) incompatibility were excluded from the study. Sixty‐seven infants met the inclusion criteria and were randomized. The prophylactic phenobarbital group received conventional supportive therapy plus phenobarbital loading dose (40 mg/kg IV) during the first four hours after birth. The erythropoietin group received conventional supportive therapy plus subcutaneous erythropoietin (1000 IU/kg per day) for three days. The supportive therapy group received conventional supportive therapy including oxygen, volume expanders, inotrope, diuretics, antibiotics, and anticonvulsants for clinically suspected seizures confirmed by aEEG. Serum levels of antioxidant enzymes (SOD and GPx), TAS, and lipid peroxidation (using MDA levels) were measured at four, 24, 48, and 72 hours and at seven days of life. Mortality, presence or absence of seizures (confirmed by aEEG), neurologic abnormalities on exam at greater than 72 hours of life and at the time of discharge (using Amiel‐Tison assessment), and long‐term neurologic outcome (including assessment for motor disability and disorders of receptive language, expressive language, and cognitive development) at three, six, nine, 12, and 18 months of age (using Bayley II assessment) were evaluated. </p> </section> <section id="CD001240-sec-0051"> <h6 class="title">Barbiturate treatment compared to other barbiturate treatment</h6> <p>We found no trials comparing barbiturate versus other barbiturate.</p> </section> <section id="CD001240-sec-0052"> <h6 class="title">Barbiturate treatment compared to other nonbarbiturate anticonvulsant treatment</h6> <p>One RCT compared barbiturate versus other nonbarbiturate anticonvulsant therapy.</p> <p><a href="./references#CD001240-bbs2-0008" title="VelaF , DuranJA , ChungaF , SerranoJS , VallsA . Preventive treatment of convulsions in perinatal asphyxia [Tratamiento profilactico de convulsiones en asfixia perinatal]. Anales Espanoles de Pediatria1987;27(2):95‐9. [PUBMED: 3662273] ">Vela 1987</a> reported on seizure activity for 17 term neonates with perinatal asphyxia randomized to prophylactic treatment with phenobarbital plus conventional therapy (nine infants) or phenytoin plus conventional therapy (eight infants) in a single‐center RCT. Eligible infants included term infants with perinatal asphyxia (defined as three of the following criteria: multiple late fetal heart rate decelerations, fetal bradycardia for more than 20 minutes, meconium‐stained fluid, Apgar score of less than 8 at five minutes, requiring mechanical ventilation, requiring IV bicarbonate therapy). Seventeen infants met the inclusion criteria and were randomized. The phenobarbital treatment group (nine infants) received conventional therapy plus phenobarbital (12 mg/kg intramuscular (IM) on day one, followed by 6 mg/kg/day through day seven). The phenytoin group (eight infants) received conventional therapy plus phenytoin (12 mg/kg IM on day one, followed by 6 mg/kg/day through day seven). The primary outcome measured was development of seizure activity. Adverse effects of medication administration (i.e. drowsiness and bradycardia) were evaluated. </p> </section> </section> <section id="CD001240-sec-0053"> <h5 class="title">Excluded studies</h5> <p>We excluded four RCTs (see <a href="./references#CD001240-sec-0112" title="">Characteristics of excluded studies</a> table). </p> <p><a href="./references#CD001240-bbs2-0011" title="RuthV , VirkolaK , PaetauR , RaivioKO . Early high‐dose phenobarbital treatment for prevention of hypoxic‐ischemic brain damage in very low birth weight infants. Journal of Pediatrics1988;112(1):81‐6. [PUBMED: 2447257] ">Ruth 1988</a> randomized premature, very low birth weight infants to receive phenobarbital or placebo following birth; perinatal asphyxia was not an eligibility criterion. </p> <p><a href="./references#CD001240-bbs2-0014" title="RochefortMJ , WilkinsonAR . The safety and efficacy of alternative anticonvulsant regimes to control newborns seizures [abstract]. Early Human Development1989;19:218. WilkinsonAR , RochefortMJ . Phenytoin reduces frequency and duration of neonatal seizures in the newborn: a randomised trial of four anticonvulsants [abstract]. Pediatric Research1989;26:522. ">Wilkinson 1989</a> compared four anticonvulsants in an RCT. The anticonvulsants were used for treatment (not prophylaxis) of EEG‐apparent seizures of any etiology, not exclusively perinatal asphyxia. Infants were a mixture of term and premature neonates. It was not possible to extract the data relating only to term infants following asphyxia. </p> <p><a href="./references#CD001240-bbs2-0010" title="KuzemkoJA , HartleyS . Treatment of cerebral irritation in the newborn: double‐blind trial with chloral hydrate and diazepam. Developmental Medicine and Child Neurology1972;14(6):740‐6. [PUBMED: 4566107] ">Kuzemko 1972</a> randomized infants to receive chloral hydrate or diazepam, agents that were not of interest in the current meta‐analysis. </p> <p><a href="./references#CD001240-bbs2-0013" title="vanRooijLG , ToetMC , vanHuffelenAC , GroenendaalF , LaanW , ZecicA , et al. Effect of treatment of subclinical neonatal seizures detected with aEEG: randomized, controlled trial. Pediatrics2010;125(2):e358‐66. [PUBMED: 20100767] ">van Rooij 2010</a> randomized infants to receive treatment (not prophylaxis) for both clinical and subclinical seizures or blinding of aEEG registration and treatment of clinical seizures only. </p> </section> </section> </section> <section id="CD001240-sec-0054"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD001240-sec-0055"> <h4 class="title">Selection bias</h4> <p>Four studies achieved randomization/allocation concealment by means of random number table (<a href="./references#CD001240-bbs2-0002" title="GathwalaG , MarwahA , GahlautV , MarwahP . Effect of high‐dose phenobarbital on oxidative stress in perinatal asphyxia: an open label randomized controlled trial. Indian Pediatrics2011;48(8):613‐7. [PUBMED: 21169640] ">Gathwala 2011</a>; <a href="./references#CD001240-bbs2-0004" title="HallRT , HallFK , DailyDK . High‐dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three‐year follow‐up. Journal of Pediatrics1998;132(2):345‐8. [PUBMED: 9506654] ">Hall 1998</a>; <a href="./references#CD001240-bbs2-0009" title="VelaphiS , MokhachaneM , MphahleleR , Beckh‐ArnoldE . Effect of prophylactic phenobarbital on seizures, encephalopathy and mortality in neonates with perinatal asphyxia. South African Journal of Child Health2013;7(1):17‐21. ">Velaphi 2013</a>), or computer‐generated random numbers (<a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>), concealed in opaque envelopes and opened at the time of randomization. In three studies, the method of randomization was by random‐draw numerical assignment (<a href="./references#CD001240-bbs2-0001" title="AvasiloaieiA , DimitriuC , MoscaluM , PaduraruL , StamatinM . High‐dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatrics International2013;55(5):589‐93. [PUBMED: 23659666] ">Avasiloaiei 2013</a>), and "list of random numbers" (<a href="./references#CD001240-bbs2-0003" title="GoldbergRN , MoscosoP , BauerCR , BloomFL , CurlessRG , BurkeB , et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. Journal of Pediatrics1986;109(5):851‐6. [PUBMED: 3534201] ">Goldberg 1986</a>), or "random numbers" (<a href="./references#CD001240-bbs2-0007" title="Vargas‐OrigelA , Espinosa‐GarciaJOG , Muniz‐QuezadaE , Vargas‐NietoMA , Aguilar‐GarciaG . Prevention of hypoxic‐ischemic encephalopathy with high‐dose, early phenobarbital therapy [Prevencion de la encefalopatia hipoxico‐isquemica mediante Fenobarbital en forma temprana y a dosis alta]. Gaceta Medica de Mexico2004;140(2):147‐53. [MEDLINE: 15162947] ">Vargas‐Origel 2004</a>) with method of allocation concealment not specified. Two studies did not specify the methods for both randomization and allocation concealment (<a href="./references#CD001240-bbs2-0005" title="RuthV , KorkmanM , LiikanenA , PaetauR . High‐dose phenobarbitol treatment to prevent postasphyxial brain damage: a 6‐year follow up [abstract]. Pediatric Research1991;30:638. [DOI: 10.1203/00006450‐199112000‐00091] ">Ruth 1991</a>; <a href="./references#CD001240-bbs2-0008" title="VelaF , DuranJA , ChungaF , SerranoJS , VallsA . Preventive treatment of convulsions in perinatal asphyxia [Tratamiento profilactico de convulsiones en asfixia perinatal]. Anales Espanoles de Pediatria1987;27(2):95‐9. [PUBMED: 3662273] ">Vela 1987</a>). </p> </section> <section id="CD001240-sec-0056"> <h4 class="title">Performance bias</h4> <p>In six studies, there was no blinding or no blinding specified and no use of placebo (<a href="./references#CD001240-bbs2-0001" title="AvasiloaieiA , DimitriuC , MoscaluM , PaduraruL , StamatinM . High‐dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatrics International2013;55(5):589‐93. [PUBMED: 23659666] ">Avasiloaiei 2013</a>; <a href="./references#CD001240-bbs2-0002" title="GathwalaG , MarwahA , GahlautV , MarwahP . Effect of high‐dose phenobarbital on oxidative stress in perinatal asphyxia: an open label randomized controlled trial. Indian Pediatrics2011;48(8):613‐7. [PUBMED: 21169640] ">Gathwala 2011</a>; <a href="./references#CD001240-bbs2-0003" title="GoldbergRN , MoscosoP , BauerCR , BloomFL , CurlessRG , BurkeB , et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. Journal of Pediatrics1986;109(5):851‐6. [PUBMED: 3534201] ">Goldberg 1986</a>; <a href="./references#CD001240-bbs2-0004" title="HallRT , HallFK , DailyDK . High‐dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three‐year follow‐up. Journal of Pediatrics1998;132(2):345‐8. [PUBMED: 9506654] ">Hall 1998</a>; <a href="./references#CD001240-bbs2-0005" title="RuthV , KorkmanM , LiikanenA , PaetauR . High‐dose phenobarbitol treatment to prevent postasphyxial brain damage: a 6‐year follow up [abstract]. Pediatric Research1991;30:638. [DOI: 10.1203/00006450‐199112000‐00091] ">Ruth 1991</a>; <a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>). In two of these studies (<a href="./references#CD001240-bbs2-0003" title="GoldbergRN , MoscosoP , BauerCR , BloomFL , CurlessRG , BurkeB , et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. Journal of Pediatrics1986;109(5):851‐6. [PUBMED: 3534201] ">Goldberg 1986</a>; <a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>), though initial blinding did not occur, long‐term follow‐up was performed by developmentalists and neurologists blinded to the infant's treatment regimen (<a href="./references#CD001240-bbs2-0003" title="GoldbergRN , MoscosoP , BauerCR , BloomFL , CurlessRG , BurkeB , et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. Journal of Pediatrics1986;109(5):851‐6. [PUBMED: 3534201] ">Goldberg 1986</a>), CSF samples were coded before sending to the laboratory to ensure blinding (<a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>), and discharge neurologic exams and cranial ultrasounds were performed by neonatologists blinded to group allocation (<a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>). Three studies administered a placebo (<a href="./references#CD001240-bbs2-0007" title="Vargas‐OrigelA , Espinosa‐GarciaJOG , Muniz‐QuezadaE , Vargas‐NietoMA , Aguilar‐GarciaG . Prevention of hypoxic‐ischemic encephalopathy with high‐dose, early phenobarbital therapy [Prevencion de la encefalopatia hipoxico‐isquemica mediante Fenobarbital en forma temprana y a dosis alta]. Gaceta Medica de Mexico2004;140(2):147‐53. [MEDLINE: 15162947] ">Vargas‐Origel 2004</a>; <a href="./references#CD001240-bbs2-0009" title="VelaphiS , MokhachaneM , MphahleleR , Beckh‐ArnoldE . Effect of prophylactic phenobarbital on seizures, encephalopathy and mortality in neonates with perinatal asphyxia. South African Journal of Child Health2013;7(1):17‐21. ">Velaphi 2013</a>) or second study drug (<a href="./references#CD001240-bbs2-0008" title="VelaF , DuranJA , ChungaF , SerranoJS , VallsA . Preventive treatment of convulsions in perinatal asphyxia [Tratamiento profilactico de convulsiones en asfixia perinatal]. Anales Espanoles de Pediatria1987;27(2):95‐9. [PUBMED: 3662273] ">Vela 1987</a>). Blinding was clearly stated in only one study (<a href="./references#CD001240-bbs2-0008" title="VelaF , DuranJA , ChungaF , SerranoJS , VallsA . Preventive treatment of convulsions in perinatal asphyxia [Tratamiento profilactico de convulsiones en asfixia perinatal]. Anales Espanoles de Pediatria1987;27(2):95‐9. [PUBMED: 3662273] ">Vela 1987</a>), and implied in two (<a href="./references#CD001240-bbs2-0007" title="Vargas‐OrigelA , Espinosa‐GarciaJOG , Muniz‐QuezadaE , Vargas‐NietoMA , Aguilar‐GarciaG . Prevention of hypoxic‐ischemic encephalopathy with high‐dose, early phenobarbital therapy [Prevencion de la encefalopatia hipoxico‐isquemica mediante Fenobarbital en forma temprana y a dosis alta]. Gaceta Medica de Mexico2004;140(2):147‐53. [MEDLINE: 15162947] ">Vargas‐Origel 2004</a>; <a href="./references#CD001240-bbs2-0009" title="VelaphiS , MokhachaneM , MphahleleR , Beckh‐ArnoldE . Effect of prophylactic phenobarbital on seizures, encephalopathy and mortality in neonates with perinatal asphyxia. South African Journal of Child Health2013;7(1):17‐21. ">Velaphi 2013</a>). </p> <p>Potential bias arising from co‐intervention remained a possibility in the six studies that did not use caretaker blinding (<a href="./references#CD001240-bbs2-0001" title="AvasiloaieiA , DimitriuC , MoscaluM , PaduraruL , StamatinM . High‐dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatrics International2013;55(5):589‐93. [PUBMED: 23659666] ">Avasiloaiei 2013</a>; <a href="./references#CD001240-bbs2-0002" title="GathwalaG , MarwahA , GahlautV , MarwahP . Effect of high‐dose phenobarbital on oxidative stress in perinatal asphyxia: an open label randomized controlled trial. Indian Pediatrics2011;48(8):613‐7. [PUBMED: 21169640] ">Gathwala 2011</a>; <a href="./references#CD001240-bbs2-0003" title="GoldbergRN , MoscosoP , BauerCR , BloomFL , CurlessRG , BurkeB , et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. Journal of Pediatrics1986;109(5):851‐6. [PUBMED: 3534201] ">Goldberg 1986</a>; <a href="./references#CD001240-bbs2-0004" title="HallRT , HallFK , DailyDK . High‐dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three‐year follow‐up. Journal of Pediatrics1998;132(2):345‐8. [PUBMED: 9506654] ">Hall 1998</a>; <a href="./references#CD001240-bbs2-0005" title="RuthV , KorkmanM , LiikanenA , PaetauR . High‐dose phenobarbitol treatment to prevent postasphyxial brain damage: a 6‐year follow up [abstract]. Pediatric Research1991;30:638. [DOI: 10.1203/00006450‐199112000‐00091] ">Ruth 1991</a>; <a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>). In <a href="./references#CD001240-bbs2-0001" title="AvasiloaieiA , DimitriuC , MoscaluM , PaduraruL , StamatinM . High‐dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatrics International2013;55(5):589‐93. [PUBMED: 23659666] ">Avasiloaiei 2013</a>, 13/23 (56.5%) infants in the supportive care group received phenobarbital for clinically suspected seizure activity confirmed by aEEG. In <a href="./references#CD001240-bbs2-0003" title="GoldbergRN , MoscosoP , BauerCR , BloomFL , CurlessRG , BurkeB , et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. Journal of Pediatrics1986;109(5):851‐6. [PUBMED: 3534201] ">Goldberg 1986</a>, 14 infants in the group treated with thiopental and 12 infants in the control group received phenobarbital for the treatment of clinical seizures. <a href="./references#CD001240-bbs2-0004" title="HallRT , HallFK , DailyDK . High‐dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three‐year follow‐up. Journal of Pediatrics1998;132(2):345‐8. [PUBMED: 9506654] ">Hall 1998</a> compared phenobarbital with conventional treatment for the prevention of seizures following asphyxia. The control group received a mean of 27 mg/kg of phenobarbital as treatment for seizures, compared to a mean of 39 mg/kg in the experimental group. The clinicians caring for the infants were aware of treatment allocation, and may have had a lower threshold to diagnose and treat clinical seizures in the control group (co‐intervention bias). Three RCTs did not clearly state the number of infants treated with additional anticonvulsants (<a href="./references#CD001240-bbs2-0002" title="GathwalaG , MarwahA , GahlautV , MarwahP . Effect of high‐dose phenobarbital on oxidative stress in perinatal asphyxia: an open label randomized controlled trial. Indian Pediatrics2011;48(8):613‐7. [PUBMED: 21169640] ">Gathwala 2011</a>; <a href="./references#CD001240-bbs2-0005" title="RuthV , KorkmanM , LiikanenA , PaetauR . High‐dose phenobarbitol treatment to prevent postasphyxial brain damage: a 6‐year follow up [abstract]. Pediatric Research1991;30:638. [DOI: 10.1203/00006450‐199112000‐00091] ">Ruth 1991</a>; <a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>). </p> </section> <section id="CD001240-sec-0057"> <h4 class="title">Attrition bias</h4> <p>There was a postrandomization loss of 23% in the study by <a href="./references#CD001240-bbs2-0004" title="HallRT , HallFK , DailyDK . High‐dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three‐year follow‐up. Journal of Pediatrics1998;132(2):345‐8. [PUBMED: 9506654] ">Hall 1998</a>; 6% of living infants in <a href="./references#CD001240-bbs2-0003" title="GoldbergRN , MoscosoP , BauerCR , BloomFL , CurlessRG , BurkeB , et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. Journal of Pediatrics1986;109(5):851‐6. [PUBMED: 3534201] ">Goldberg 1986;</a> 3% of living infants in <a href="./references#CD001240-bbs2-0002" title="GathwalaG , MarwahA , GahlautV , MarwahP . Effect of high‐dose phenobarbital on oxidative stress in perinatal asphyxia: an open label randomized controlled trial. Indian Pediatrics2011;48(8):613‐7. [PUBMED: 21169640] ">Gathwala 2011</a>; and 0% in <a href="./references#CD001240-bbs2-0001" title="AvasiloaieiA , DimitriuC , MoscaluM , PaduraruL , StamatinM . High‐dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatrics International2013;55(5):589‐93. [PUBMED: 23659666] ">Avasiloaiei 2013</a>, <a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>, <a href="./references#CD001240-bbs2-0007" title="Vargas‐OrigelA , Espinosa‐GarciaJOG , Muniz‐QuezadaE , Vargas‐NietoMA , Aguilar‐GarciaG . Prevention of hypoxic‐ischemic encephalopathy with high‐dose, early phenobarbital therapy [Prevencion de la encefalopatia hipoxico‐isquemica mediante Fenobarbital en forma temprana y a dosis alta]. Gaceta Medica de Mexico2004;140(2):147‐53. [MEDLINE: 15162947] ">Vargas‐Origel 2004</a>, <a href="./references#CD001240-bbs2-0009" title="VelaphiS , MokhachaneM , MphahleleR , Beckh‐ArnoldE . Effect of prophylactic phenobarbital on seizures, encephalopathy and mortality in neonates with perinatal asphyxia. South African Journal of Child Health2013;7(1):17‐21. ">Velaphi 2013</a>, and <a href="./references#CD001240-bbs2-0008" title="VelaF , DuranJA , ChungaF , SerranoJS , VallsA . Preventive treatment of convulsions in perinatal asphyxia [Tratamiento profilactico de convulsiones en asfixia perinatal]. Anales Espanoles de Pediatria1987;27(2):95‐9. [PUBMED: 3662273] ">Vela 1987</a>. There were no data to calculate attrition in <a href="./references#CD001240-bbs2-0005" title="RuthV , KorkmanM , LiikanenA , PaetauR . High‐dose phenobarbitol treatment to prevent postasphyxial brain damage: a 6‐year follow up [abstract]. Pediatric Research1991;30:638. [DOI: 10.1203/00006450‐199112000‐00091] ">Ruth 1991</a>. </p> </section> <section id="CD001240-sec-0058"> <h4 class="title">Detection bias</h4> <p>Only four studies had blind assessment of outcome (<a href="./references#CD001240-bbs2-0003" title="GoldbergRN , MoscosoP , BauerCR , BloomFL , CurlessRG , BurkeB , et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. Journal of Pediatrics1986;109(5):851‐6. [PUBMED: 3534201] ">Goldberg 1986</a>; <a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>; <a href="./references#CD001240-bbs2-0008" title="VelaF , DuranJA , ChungaF , SerranoJS , VallsA . Preventive treatment of convulsions in perinatal asphyxia [Tratamiento profilactico de convulsiones en asfixia perinatal]. Anales Espanoles de Pediatria1987;27(2):95‐9. [PUBMED: 3662273] ">Vela 1987</a>; <a href="./references#CD001240-bbs2-0009" title="VelaphiS , MokhachaneM , MphahleleR , Beckh‐ArnoldE . Effect of prophylactic phenobarbital on seizures, encephalopathy and mortality in neonates with perinatal asphyxia. South African Journal of Child Health2013;7(1):17‐21. ">Velaphi 2013</a>), and only one of these assessed outcomes outside the neonatal period (<a href="./references#CD001240-bbs2-0003" title="GoldbergRN , MoscosoP , BauerCR , BloomFL , CurlessRG , BurkeB , et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. Journal of Pediatrics1986;109(5):851‐6. [PUBMED: 3534201] ">Goldberg 1986</a>). <a href="./references#CD001240-bbs2-0008" title="VelaF , DuranJA , ChungaF , SerranoJS , VallsA . Preventive treatment of convulsions in perinatal asphyxia [Tratamiento profilactico de convulsiones en asfixia perinatal]. Anales Espanoles de Pediatria1987;27(2):95‐9. [PUBMED: 3662273] ">Vela 1987</a> utilized a double‐blind study design. <a href="./references#CD001240-bbs2-0003" title="GoldbergRN , MoscosoP , BauerCR , BloomFL , CurlessRG , BurkeB , et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. Journal of Pediatrics1986;109(5):851‐6. [PUBMED: 3534201] ">Goldberg 1986</a> used a blinded outcome assessment at one to three years but was not blinded for short‐term outcomes. </p> </section> </section> <section id="CD001240-sec-0059"> <h3 class="title" id="CD001240-sec-0059">Effects of interventions</h3> <p>See: <a href="./full#CD001240-tbl-0001"><b>Summary of findings for the main comparison</b> Barbiturate treatment compared to placebo or no treatment</a> </p> <p>Nine RCTS enrolled 456 term and late preterm infants aged less than three days old with perinatal asphyxia without evidence of seizures to determine the effect of administering prophylactic barbiturate therapy on death (<a href="./references#CD001240-bbs2-0001" title="AvasiloaieiA , DimitriuC , MoscaluM , PaduraruL , StamatinM . High‐dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatrics International2013;55(5):589‐93. [PUBMED: 23659666] ">Avasiloaiei 2013</a>; <a href="./references#CD001240-bbs2-0002" title="GathwalaG , MarwahA , GahlautV , MarwahP . Effect of high‐dose phenobarbital on oxidative stress in perinatal asphyxia: an open label randomized controlled trial. Indian Pediatrics2011;48(8):613‐7. [PUBMED: 21169640] ">Gathwala 2011</a>; <a href="./references#CD001240-bbs2-0003" title="GoldbergRN , MoscosoP , BauerCR , BloomFL , CurlessRG , BurkeB , et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. Journal of Pediatrics1986;109(5):851‐6. [PUBMED: 3534201] ">Goldberg 1986</a>; <a href="./references#CD001240-bbs2-0004" title="HallRT , HallFK , DailyDK . High‐dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three‐year follow‐up. Journal of Pediatrics1998;132(2):345‐8. [PUBMED: 9506654] ">Hall 1998</a>; <a href="./references#CD001240-bbs2-0005" title="RuthV , KorkmanM , LiikanenA , PaetauR . High‐dose phenobarbitol treatment to prevent postasphyxial brain damage: a 6‐year follow up [abstract]. Pediatric Research1991;30:638. [DOI: 10.1203/00006450‐199112000‐00091] ">Ruth 1991</a>; <a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>; <a href="./references#CD001240-bbs2-0007" title="Vargas‐OrigelA , Espinosa‐GarciaJOG , Muniz‐QuezadaE , Vargas‐NietoMA , Aguilar‐GarciaG . Prevention of hypoxic‐ischemic encephalopathy with high‐dose, early phenobarbital therapy [Prevencion de la encefalopatia hipoxico‐isquemica mediante Fenobarbital en forma temprana y a dosis alta]. Gaceta Medica de Mexico2004;140(2):147‐53. [MEDLINE: 15162947] ">Vargas‐Origel 2004</a>; <a href="./references#CD001240-bbs2-0009" title="VelaphiS , MokhachaneM , MphahleleR , Beckh‐ArnoldE . Effect of prophylactic phenobarbital on seizures, encephalopathy and mortality in neonates with perinatal asphyxia. South African Journal of Child Health2013;7(1):17‐21. ">Velaphi 2013</a>), short‐term medical outcomes (<a href="./references#CD001240-bbs2-0002" title="GathwalaG , MarwahA , GahlautV , MarwahP . Effect of high‐dose phenobarbital on oxidative stress in perinatal asphyxia: an open label randomized controlled trial. Indian Pediatrics2011;48(8):613‐7. [PUBMED: 21169640] ">Gathwala 2011</a>; <a href="./references#CD001240-bbs2-0003" title="GoldbergRN , MoscosoP , BauerCR , BloomFL , CurlessRG , BurkeB , et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. Journal of Pediatrics1986;109(5):851‐6. [PUBMED: 3534201] ">Goldberg 1986</a>; <a href="./references#CD001240-bbs2-0004" title="HallRT , HallFK , DailyDK . High‐dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three‐year follow‐up. Journal of Pediatrics1998;132(2):345‐8. [PUBMED: 9506654] ">Hall 1998</a>), short‐term neurologic outcomes (<a href="./references#CD001240-bbs2-0001" title="AvasiloaieiA , DimitriuC , MoscaluM , PaduraruL , StamatinM . High‐dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatrics International2013;55(5):589‐93. [PUBMED: 23659666] ">Avasiloaiei 2013</a>; <a href="./references#CD001240-bbs2-0003" title="GoldbergRN , MoscosoP , BauerCR , BloomFL , CurlessRG , BurkeB , et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. Journal of Pediatrics1986;109(5):851‐6. [PUBMED: 3534201] ">Goldberg 1986</a>; <a href="./references#CD001240-bbs2-0004" title="HallRT , HallFK , DailyDK . High‐dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three‐year follow‐up. Journal of Pediatrics1998;132(2):345‐8. [PUBMED: 9506654] ">Hall 1998</a>; <a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>; <a href="./references#CD001240-bbs2-0007" title="Vargas‐OrigelA , Espinosa‐GarciaJOG , Muniz‐QuezadaE , Vargas‐NietoMA , Aguilar‐GarciaG . Prevention of hypoxic‐ischemic encephalopathy with high‐dose, early phenobarbital therapy [Prevencion de la encefalopatia hipoxico‐isquemica mediante Fenobarbital en forma temprana y a dosis alta]. Gaceta Medica de Mexico2004;140(2):147‐53. [MEDLINE: 15162947] ">Vargas‐Origel 2004</a>; <a href="./references#CD001240-bbs2-0008" title="VelaF , DuranJA , ChungaF , SerranoJS , VallsA . Preventive treatment of convulsions in perinatal asphyxia [Tratamiento profilactico de convulsiones en asfixia perinatal]. Anales Espanoles de Pediatria1987;27(2):95‐9. [PUBMED: 3662273] ">Vela 1987</a>; <a href="./references#CD001240-bbs2-0009" title="VelaphiS , MokhachaneM , MphahleleR , Beckh‐ArnoldE . Effect of prophylactic phenobarbital on seizures, encephalopathy and mortality in neonates with perinatal asphyxia. South African Journal of Child Health2013;7(1):17‐21. ">Velaphi 2013</a>), and longer‐term neurodevelopmental outcomes (<a href="./references#CD001240-bbs2-0001" title="AvasiloaieiA , DimitriuC , MoscaluM , PaduraruL , StamatinM . High‐dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatrics International2013;55(5):589‐93. [PUBMED: 23659666] ">Avasiloaiei 2013</a>; <a href="./references#CD001240-bbs2-0003" title="GoldbergRN , MoscosoP , BauerCR , BloomFL , CurlessRG , BurkeB , et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. Journal of Pediatrics1986;109(5):851‐6. [PUBMED: 3534201] ">Goldberg 1986</a>; <a href="./references#CD001240-bbs2-0004" title="HallRT , HallFK , DailyDK . High‐dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three‐year follow‐up. Journal of Pediatrics1998;132(2):345‐8. [PUBMED: 9506654] ">Hall 1998</a>; <a href="./references#CD001240-bbs2-0005" title="RuthV , KorkmanM , LiikanenA , PaetauR . High‐dose phenobarbitol treatment to prevent postasphyxial brain damage: a 6‐year follow up [abstract]. Pediatric Research1991;30:638. [DOI: 10.1203/00006450‐199112000‐00091] ">Ruth 1991</a>; <a href="./references#CD001240-bbs2-0007" title="Vargas‐OrigelA , Espinosa‐GarciaJOG , Muniz‐QuezadaE , Vargas‐NietoMA , Aguilar‐GarciaG . Prevention of hypoxic‐ischemic encephalopathy with high‐dose, early phenobarbital therapy [Prevencion de la encefalopatia hipoxico‐isquemica mediante Fenobarbital en forma temprana y a dosis alta]. Gaceta Medica de Mexico2004;140(2):147‐53. [MEDLINE: 15162947] ">Vargas‐Origel 2004</a>). </p> <p>Data presented allowed for analysis according to subgroups for type of barbiturate, severity of HIE, and studies in low‐ and middle‐income countries. </p> <section id="CD001240-sec-0060"> <h4 class="title">Barbiturate treatment compared to placebo or no treatment</h4> <section id="CD001240-sec-0061"> <h5 class="title">Primary outcomes</h5> <section id="CD001240-sec-0062"> <h6 class="title">Death or severe neurodevelopmental disability (outcome 1.1)</h6> <p>One trial permitted the assessment of the effect of barbiturate versus control on the composite outcome of death or severe neurodevelopmental disability (<a href="./references#CD001240-bbs2-0004" title="HallRT , HallFK , DailyDK . High‐dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three‐year follow‐up. Journal of Pediatrics1998;132(2):345‐8. [PUBMED: 9506654] ">Hall 1998</a>). There were 31 infants included in the results of this trial, of whom 17 either died or had severe neurodevelopmental disability. This study demonstrated a significant reduction in the combined outcome of death or severe neurodevelopmental disability in infants treated with phenobarbital (RR 0.33, 95% CI 0.14 to 0.78; RD ‐0.55, 95% CI ‐0.84 to ‐0.25; NNTB 2, 95% CI 1 to 4; 1 study, 31 infants) (very low quality evidence) (<a href="./references#CD001240-fig-0003" title="">Analysis 1.1</a>). Heterogeneity of the effect was not applicable. </p> </section> </section> <section id="CD001240-sec-0063"> <h5 class="title">Secondary outcomes</h5> <section id="CD001240-sec-0064"> <h6 class="title">Death (at any time) (outcome 1.2)</h6> <p>Eight trials comparing barbiturates with conventional therapy reported on death (<a href="./references#CD001240-bbs2-0001" title="AvasiloaieiA , DimitriuC , MoscaluM , PaduraruL , StamatinM . High‐dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatrics International2013;55(5):589‐93. [PUBMED: 23659666] ">Avasiloaiei 2013</a>; <a href="./references#CD001240-bbs2-0002" title="GathwalaG , MarwahA , GahlautV , MarwahP . Effect of high‐dose phenobarbital on oxidative stress in perinatal asphyxia: an open label randomized controlled trial. Indian Pediatrics2011;48(8):613‐7. [PUBMED: 21169640] ">Gathwala 2011</a>; <a href="./references#CD001240-bbs2-0003" title="GoldbergRN , MoscosoP , BauerCR , BloomFL , CurlessRG , BurkeB , et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. Journal of Pediatrics1986;109(5):851‐6. [PUBMED: 3534201] ">Goldberg 1986</a>; <a href="./references#CD001240-bbs2-0004" title="HallRT , HallFK , DailyDK . High‐dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three‐year follow‐up. Journal of Pediatrics1998;132(2):345‐8. [PUBMED: 9506654] ">Hall 1998</a>; <a href="./references#CD001240-bbs2-0005" title="RuthV , KorkmanM , LiikanenA , PaetauR . High‐dose phenobarbitol treatment to prevent postasphyxial brain damage: a 6‐year follow up [abstract]. Pediatric Research1991;30:638. [DOI: 10.1203/00006450‐199112000‐00091] ">Ruth 1991</a>; <a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>; <a href="./references#CD001240-bbs2-0007" title="Vargas‐OrigelA , Espinosa‐GarciaJOG , Muniz‐QuezadaE , Vargas‐NietoMA , Aguilar‐GarciaG . Prevention of hypoxic‐ischemic encephalopathy with high‐dose, early phenobarbital therapy [Prevencion de la encefalopatia hipoxico‐isquemica mediante Fenobarbital en forma temprana y a dosis alta]. Gaceta Medica de Mexico2004;140(2):147‐53. [MEDLINE: 15162947] ">Vargas‐Origel 2004</a>; <a href="./references#CD001240-bbs2-0009" title="VelaphiS , MokhachaneM , MphahleleR , Beckh‐ArnoldE . Effect of prophylactic phenobarbital on seizures, encephalopathy and mortality in neonates with perinatal asphyxia. South African Journal of Child Health2013;7(1):17‐21. ">Velaphi 2013</a>). No studies found a statistically significant difference in mortality rates between the experimental and control groups. The meta‐analysis of all eight trials demonstrated no significant difference in death between the two groups (typical RR 0.88, 95% CI 0.55 to 1.42; 8 trials, 429 infants) (low quality evidence) (<a href="./references#CD001240-fig-0004" title="">Analysis 1.2</a>.1). There was no evidence of heterogeneity of effect (I<sup>2</sup> = 0%). </p> <p>Seven trials compared phenobarbital versus control (<a href="./references#CD001240-bbs2-0001" title="AvasiloaieiA , DimitriuC , MoscaluM , PaduraruL , StamatinM . High‐dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatrics International2013;55(5):589‐93. [PUBMED: 23659666] ">Avasiloaiei 2013</a>; <a href="./references#CD001240-bbs2-0002" title="GathwalaG , MarwahA , GahlautV , MarwahP . Effect of high‐dose phenobarbital on oxidative stress in perinatal asphyxia: an open label randomized controlled trial. Indian Pediatrics2011;48(8):613‐7. [PUBMED: 21169640] ">Gathwala 2011</a>; <a href="./references#CD001240-bbs2-0004" title="HallRT , HallFK , DailyDK . High‐dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three‐year follow‐up. Journal of Pediatrics1998;132(2):345‐8. [PUBMED: 9506654] ">Hall 1998</a>; <a href="./references#CD001240-bbs2-0005" title="RuthV , KorkmanM , LiikanenA , PaetauR . High‐dose phenobarbitol treatment to prevent postasphyxial brain damage: a 6‐year follow up [abstract]. Pediatric Research1991;30:638. [DOI: 10.1203/00006450‐199112000‐00091] ">Ruth 1991</a>; <a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>; <a href="./references#CD001240-bbs2-0007" title="Vargas‐OrigelA , Espinosa‐GarciaJOG , Muniz‐QuezadaE , Vargas‐NietoMA , Aguilar‐GarciaG . Prevention of hypoxic‐ischemic encephalopathy with high‐dose, early phenobarbital therapy [Prevencion de la encefalopatia hipoxico‐isquemica mediante Fenobarbital en forma temprana y a dosis alta]. Gaceta Medica de Mexico2004;140(2):147‐53. [MEDLINE: 15162947] ">Vargas‐Origel 2004</a>; <a href="./references#CD001240-bbs2-0009" title="VelaphiS , MokhachaneM , MphahleleR , Beckh‐ArnoldE . Effect of prophylactic phenobarbital on seizures, encephalopathy and mortality in neonates with perinatal asphyxia. South African Journal of Child Health2013;7(1):17‐21. ">Velaphi 2013</a>). Meta‐analysis showed no statistically significant effect on mortality (typical RR 0.81, 95% CI 0.48 to 1.35; 7 trials, 398 infants) (<a href="./references#CD001240-fig-0004" title="">Analysis 1.2</a>.2). There was no evidence of heterogeneity of effect (I<sup>2</sup> = 0%). </p> <p>The one study that compared thiopentone versus control also showed no difference in mortality (RR 1.47, 95% CI 0.42 to 5.14; 1 trial, 31 infants) (<a href="./references#CD001240-bbs2-0003" title="GoldbergRN , MoscosoP , BauerCR , BloomFL , CurlessRG , BurkeB , et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. Journal of Pediatrics1986;109(5):851‐6. [PUBMED: 3534201] ">Goldberg 1986</a>). </p> <p>Four trials presented results for the subset of infants with Sarnat 2 or greater for barbiturate versus control (<a href="./references#CD001240-bbs2-0003" title="GoldbergRN , MoscosoP , BauerCR , BloomFL , CurlessRG , BurkeB , et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. Journal of Pediatrics1986;109(5):851‐6. [PUBMED: 3534201] ">Goldberg 1986</a>; <a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>; <a href="./references#CD001240-bbs2-0007" title="Vargas‐OrigelA , Espinosa‐GarciaJOG , Muniz‐QuezadaE , Vargas‐NietoMA , Aguilar‐GarciaG . Prevention of hypoxic‐ischemic encephalopathy with high‐dose, early phenobarbital therapy [Prevencion de la encefalopatia hipoxico‐isquemica mediante Fenobarbital en forma temprana y a dosis alta]. Gaceta Medica de Mexico2004;140(2):147‐53. [MEDLINE: 15162947] ">Vargas‐Origel 2004</a>; <a href="./references#CD001240-bbs2-0009" title="VelaphiS , MokhachaneM , MphahleleR , Beckh‐ArnoldE . Effect of prophylactic phenobarbital on seizures, encephalopathy and mortality in neonates with perinatal asphyxia. South African Journal of Child Health2013;7(1):17‐21. ">Velaphi 2013</a>). Meta‐analysis showed no difference in mortality (typical RR 0.89, 95% CI 0.45 to 1.77; 4 trials, 243 infants) (<a href="./references#CD001240-fig-0004" title="">Analysis 1.2</a>.3). There was no evidence of heterogeneity of effect (I<sup>2</sup> = 0%). </p> <p>Five trials were conducted in low‐ or middle‐income countries (<a href="./references#CD001240-bbs2-0001" title="AvasiloaieiA , DimitriuC , MoscaluM , PaduraruL , StamatinM . High‐dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatrics International2013;55(5):589‐93. [PUBMED: 23659666] ">Avasiloaiei 2013</a>; <a href="./references#CD001240-bbs2-0002" title="GathwalaG , MarwahA , GahlautV , MarwahP . Effect of high‐dose phenobarbital on oxidative stress in perinatal asphyxia: an open label randomized controlled trial. Indian Pediatrics2011;48(8):613‐7. [PUBMED: 21169640] ">Gathwala 2011</a>; <a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>; <a href="./references#CD001240-bbs2-0007" title="Vargas‐OrigelA , Espinosa‐GarciaJOG , Muniz‐QuezadaE , Vargas‐NietoMA , Aguilar‐GarciaG . Prevention of hypoxic‐ischemic encephalopathy with high‐dose, early phenobarbital therapy [Prevencion de la encefalopatia hipoxico‐isquemica mediante Fenobarbital en forma temprana y a dosis alta]. Gaceta Medica de Mexico2004;140(2):147‐53. [MEDLINE: 15162947] ">Vargas‐Origel 2004</a>; <a href="./references#CD001240-bbs2-0009" title="VelaphiS , MokhachaneM , MphahleleR , Beckh‐ArnoldE . Effect of prophylactic phenobarbital on seizures, encephalopathy and mortality in neonates with perinatal asphyxia. South African Journal of Child Health2013;7(1):17‐21. ">Velaphi 2013</a>). Meta‐analysis showed no difference in mortality (typical RR 0.77, 95% CI 0.42 to 1.42; 5 trials, 329 infants) (<a href="./references#CD001240-fig-0004" title="">Analysis 1.2</a>.4). There was no evidence of heterogeneity of effect (I<sup>2</sup> = 0%). </p> </section> <section id="CD001240-sec-0065"> <h6 class="title">Severe neurodevelopmental disability in survivors examined (outcome 1.3)</h6> <p>One trial including 31 infants comparing prophylactic barbiturate therapy with conventional therapy reported data on the effect on major neurodevelopmental disability in survivors (<a href="./references#CD001240-bbs2-0004" title="HallRT , HallFK , DailyDK . High‐dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three‐year follow‐up. Journal of Pediatrics1998;132(2):345‐8. [PUBMED: 9506654] ">Hall 1998</a>). Of the 31 infants in this trial, 11 had severe neurodevelopmental disability. This study demonstrated a significant reduction in severe neurodevelopmental disability in infants treated with phenobarbital (RR 0.24, 95% CI 0.06 to 0.92; RD ‐0.43, 95% CI ‐0.73 to ‐0.13; NNTB 2, 95% CI 1 to 8; 1 study, 31 infants) (very low quality evidence) (<a href="./references#CD001240-fig-0005" title="">Analysis 1.3</a>). Heterogeneity of effect was not applicable. </p> </section> <section id="CD001240-sec-0066"> <h6 class="title">Each component of major neurodevelopmental disability</h6> <section id="CD001240-sec-0067"> <p><b>Cerebral palsy in survivors assessed (outcome 1.4)</b></p> <p>Two trials comparing barbiturates (both used phenobarbital) with conventional therapy reported on the long‐term outcome of cerebral palsy (<a href="./references#CD001240-bbs2-0004" title="HallRT , HallFK , DailyDK . High‐dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three‐year follow‐up. Journal of Pediatrics1998;132(2):345‐8. [PUBMED: 9506654] ">Hall 1998</a>; <a href="./references#CD001240-bbs2-0005" title="RuthV , KorkmanM , LiikanenA , PaetauR . High‐dose phenobarbitol treatment to prevent postasphyxial brain damage: a 6‐year follow up [abstract]. Pediatric Research1991;30:638. [DOI: 10.1203/00006450‐199112000‐00091] ">Ruth 1991</a>). There were 69 infants, of these 13 were identified as having cerebral palsy. Neither study found a statistically significant difference in rates of cerebral palsy between the experimental and control groups. The meta‐analysis of the two trials demonstrated no significant difference in cerebral palsy between the two groups (typical RR 0.58, 95% CI 0.19 to 1.70; 2 trials, 69 infants) (very low quality evidence) (<a href="./references#CD001240-fig-0006" title="">Analysis 1.4</a>). There was moderate heterogeneity of effect (I<sup>2</sup> = 67%). </p> </section> <section id="CD001240-sec-0068"> <p><b>Developmental delay or intellectual impairment in survivors assessed (outcome 1.5)</b></p> <p>Two trials comparing barbiturates with conventional therapy reported on developmental delay in survivors (<a href="./references#CD001240-bbs2-0001" title="AvasiloaieiA , DimitriuC , MoscaluM , PaduraruL , StamatinM . High‐dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatrics International2013;55(5):589‐93. [PUBMED: 23659666] ">Avasiloaiei 2013</a>; <a href="./references#CD001240-bbs2-0003" title="GoldbergRN , MoscosoP , BauerCR , BloomFL , CurlessRG , BurkeB , et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. Journal of Pediatrics1986;109(5):851‐6. [PUBMED: 3534201] ">Goldberg 1986</a>). There were 63 infants, of these 17 were identified as having developmental delay. Neither study found a statistically significant difference in the rates of developmental delay between the experimental and control groups. Meta‐analysis of the two trials found no statistically significant difference in developmental delay between the two groups (typical RR 0.54, 95% CI 0.24 to 1.19; 2 trials, 63 infants) (very low quality evidence) (<a href="./references#CD001240-fig-0007" title="">Analysis 1.5</a>). There was moderate heterogeneity of effect (I<sup>2</sup> = 50%). </p> <p>The one trial comparing phenobarbital versus conventional therapy showed no difference in developmental delay between the groups (RR 0.19, 95% CI 0.02 to 1.49; 1 trial, 41 infants) (<a href="./references#CD001240-fig-0007" title="">Analysis 1.5</a>.2) (<a href="./references#CD001240-bbs2-0001" title="AvasiloaieiA , DimitriuC , MoscaluM , PaduraruL , StamatinM . High‐dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatrics International2013;55(5):589‐93. [PUBMED: 23659666] ">Avasiloaiei 2013</a>). The one trial that compared thiopentone versus control also showed no difference in developmental delay (RR 0.83, 95% CI 0.36 to 1.94; 1 trial, 31 infants) (<a href="./references#CD001240-fig-0007" title="">Analysis 1.5</a>.3) (<a href="./references#CD001240-bbs2-0003" title="GoldbergRN , MoscosoP , BauerCR , BloomFL , CurlessRG , BurkeB , et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. Journal of Pediatrics1986;109(5):851‐6. [PUBMED: 3534201] ">Goldberg 1986</a>). </p> <p>One trial identified results for the subset of infants with Sarnat 2 or greater for barbiturate versus control (<a href="./references#CD001240-bbs2-0003" title="GoldbergRN , MoscosoP , BauerCR , BloomFL , CurlessRG , BurkeB , et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. Journal of Pediatrics1986;109(5):851‐6. [PUBMED: 3534201] ">Goldberg 1986</a>). This trial showed no difference in developmental delay between the two groups for this subset of infants (RR 0.83, 95% CI 0.36 to 1.94); 1 trial, 31 infants) (<a href="./references#CD001240-fig-0007" title="">Analysis 1.5</a>.4). </p> <p>One trial was conducted in a low or middle income country (<a href="./references#CD001240-bbs2-0001" title="AvasiloaieiA , DimitriuC , MoscaluM , PaduraruL , StamatinM . High‐dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatrics International2013;55(5):589‐93. [PUBMED: 23659666] ">Avasiloaiei 2013</a>), this trial did not demonstrate a difference in developmental delay between the groups (RR 0.19, 95% CI 0.02 to 1.49; 1 trial, 41 infants) (<a href="./references#CD001240-fig-0007" title="">Analysis 1.5</a>.5). Heterogeneity of effect was not applicable. </p> </section> <section id="CD001240-sec-0069"> <p><b>IQ in survivors (outcome 1.6)</b></p> <p>One trial comparing barbiturate with conventional therapy reported on IQ in survivors (<a href="./references#CD001240-bbs2-0005" title="RuthV , KorkmanM , LiikanenA , PaetauR . High‐dose phenobarbitol treatment to prevent postasphyxial brain damage: a 6‐year follow up [abstract]. Pediatric Research1991;30:638. [DOI: 10.1203/00006450‐199112000‐00091] ">Ruth 1991</a>). There was no significant difference in the IQ of survivors at six years of age, treated with phenobarbital versus controls (MD ‐3.00, 95% CI ‐21.57 to 15.57; 1 trial, 30 infants) (<a href="./references#CD001240-fig-0008" title="">Analysis 1.6</a>). </p> </section> <section id="CD001240-sec-0070"> <p><b>Blindness vision (less than 6/60 in both eyes)</b></p> <p>We found no trials reporting blindness vision.</p> </section> <section id="CD001240-sec-0071"> <p><b>Sensorineural deafness requiring amplification</b></p> <p>We found no trials reporting sensorineural deafness requiring amplification.</p> </section> <section id="CD001240-sec-0072"> <p><b>Seizures within the neonatal period (outcome 1.7)</b></p> <p>Six trials comparing barbiturates with conventional therapy reported on seizures in the neonatal period (<a href="./references#CD001240-bbs2-0001" title="AvasiloaieiA , DimitriuC , MoscaluM , PaduraruL , StamatinM . High‐dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatrics International2013;55(5):589‐93. [PUBMED: 23659666] ">Avasiloaiei 2013</a>; <a href="./references#CD001240-bbs2-0003" title="GoldbergRN , MoscosoP , BauerCR , BloomFL , CurlessRG , BurkeB , et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. Journal of Pediatrics1986;109(5):851‐6. [PUBMED: 3534201] ">Goldberg 1986</a>; <a href="./references#CD001240-bbs2-0004" title="HallRT , HallFK , DailyDK . High‐dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three‐year follow‐up. Journal of Pediatrics1998;132(2):345‐8. [PUBMED: 9506654] ">Hall 1998</a>; <a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>; <a href="./references#CD001240-bbs2-0007" title="Vargas‐OrigelA , Espinosa‐GarciaJOG , Muniz‐QuezadaE , Vargas‐NietoMA , Aguilar‐GarciaG . Prevention of hypoxic‐ischemic encephalopathy with high‐dose, early phenobarbital therapy [Prevencion de la encefalopatia hipoxico‐isquemica mediante Fenobarbital en forma temprana y a dosis alta]. Gaceta Medica de Mexico2004;140(2):147‐53. [MEDLINE: 15162947] ">Vargas‐Origel 2004</a>; <a href="./references#CD001240-bbs2-0009" title="VelaphiS , MokhachaneM , MphahleleR , Beckh‐ArnoldE . Effect of prophylactic phenobarbital on seizures, encephalopathy and mortality in neonates with perinatal asphyxia. South African Journal of Child Health2013;7(1):17‐21. ">Velaphi 2013</a>). There were 319 infants, of these 121 infants developed seizures in the neonatal period. One study found a statistically significant reduction in seizures for the experimental group compared to controls (<a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>). Three studies showed a nonsignificant reduction in seizures in favor of the experimental group (<a href="./references#CD001240-bbs2-0001" title="AvasiloaieiA , DimitriuC , MoscaluM , PaduraruL , StamatinM . High‐dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatrics International2013;55(5):589‐93. [PUBMED: 23659666] ">Avasiloaiei 2013</a>; <a href="./references#CD001240-bbs2-0004" title="HallRT , HallFK , DailyDK . High‐dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three‐year follow‐up. Journal of Pediatrics1998;132(2):345‐8. [PUBMED: 9506654] ">Hall 1998</a>; <a href="./references#CD001240-bbs2-0009" title="VelaphiS , MokhachaneM , MphahleleR , Beckh‐ArnoldE . Effect of prophylactic phenobarbital on seizures, encephalopathy and mortality in neonates with perinatal asphyxia. South African Journal of Child Health2013;7(1):17‐21. ">Velaphi 2013</a>). Meta‐analysis of all six trials demonstrated a statistically significant reduction in seizures for the experimental group compared to controls (typical RR 0.62, 95% CI 0.48 to 0.81; typical RD ‐0.18, 95% CI ‐0.27 to ‐0.09; NNTB 5, 95% CI 4 to 11; 6 studies, 319 infants) (low quality evidence) (<a href="./references#CD001240-fig-0009" title="">Analysis 1.7</a>.1) (<a href="#CD001240-fig-0002">Figure 2</a>). There was moderate heterogeneity of effect (I<sup>2</sup> = 68%). </p> <div class="figure" id="CD001240-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Barbiturates versus control, outcome: 1.7 Seizures within neonatal period." data-id="CD001240-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_n/nCD001240-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Barbiturates versus control, outcome: 1.7 Seizures within neonatal period. </p> </div> </div> </div> <p>Meta‐analysis of the five trials that compared phenobarbital versus control showed a statistically significant difference in seizures between the two groups in favor of the experimental group (typical RR 0.53, 95% CI 0.38 to 0.73; typical RD ‐0.20, 95% CI ‐0.30 to ‐0.11; NNTB 5, 95% CI 3 to 9; 5 studies, 288 infants) (<a href="./references#CD001240-fig-0009" title="">Analysis 1.7</a>.2) (<a href="./references#CD001240-bbs2-0001" title="AvasiloaieiA , DimitriuC , MoscaluM , PaduraruL , StamatinM . High‐dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatrics International2013;55(5):589‐93. [PUBMED: 23659666] ">Avasiloaiei 2013</a>; <a href="./references#CD001240-bbs2-0004" title="HallRT , HallFK , DailyDK . High‐dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three‐year follow‐up. Journal of Pediatrics1998;132(2):345‐8. [PUBMED: 9506654] ">Hall 1998</a>; <a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>; <a href="./references#CD001240-bbs2-0007" title="Vargas‐OrigelA , Espinosa‐GarciaJOG , Muniz‐QuezadaE , Vargas‐NietoMA , Aguilar‐GarciaG . Prevention of hypoxic‐ischemic encephalopathy with high‐dose, early phenobarbital therapy [Prevencion de la encefalopatia hipoxico‐isquemica mediante Fenobarbital en forma temprana y a dosis alta]. Gaceta Medica de Mexico2004;140(2):147‐53. [MEDLINE: 15162947] ">Vargas‐Origel 2004</a>; <a href="./references#CD001240-bbs2-0009" title="VelaphiS , MokhachaneM , MphahleleR , Beckh‐ArnoldE . Effect of prophylactic phenobarbital on seizures, encephalopathy and mortality in neonates with perinatal asphyxia. South African Journal of Child Health2013;7(1):17‐21. ">Velaphi 2013</a>). There was no evidence of heterogeneity of effect (I<sup>2</sup> = 0%). The one study that compared thiopentone versus control showed no difference in seizures between the two groups (RR 1.09, 95% CI 0.80 to 1.50; 1 trial, 31 infants) (<a href="./references#CD001240-bbs2-0003" title="GoldbergRN , MoscosoP , BauerCR , BloomFL , CurlessRG , BurkeB , et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. Journal of Pediatrics1986;109(5):851‐6. [PUBMED: 3534201] ">Goldberg 1986</a>). </p> <p>Meta‐analysis of the four trials that identified results for the subset of infants with Sarnat 2 or greater for barbiturate versus control also showed a significant reduction in seizures in the experimental group compared to the control group (typical RR 0.64, 95% CI 0.47 to 0.89; typical RD ‐0.14, 95% CI ‐0.25 to ‐0.04; NNTB 7, 95% CI 4 to 25; 4 studies, 243 infants) (<a href="./references#CD001240-fig-0009" title="">Analysis 1.7</a>.3) (<a href="./references#CD001240-bbs2-0003" title="GoldbergRN , MoscosoP , BauerCR , BloomFL , CurlessRG , BurkeB , et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. Journal of Pediatrics1986;109(5):851‐6. [PUBMED: 3534201] ">Goldberg 1986</a>; <a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>; <a href="./references#CD001240-bbs2-0007" title="Vargas‐OrigelA , Espinosa‐GarciaJOG , Muniz‐QuezadaE , Vargas‐NietoMA , Aguilar‐GarciaG . Prevention of hypoxic‐ischemic encephalopathy with high‐dose, early phenobarbital therapy [Prevencion de la encefalopatia hipoxico‐isquemica mediante Fenobarbital en forma temprana y a dosis alta]. Gaceta Medica de Mexico2004;140(2):147‐53. [MEDLINE: 15162947] ">Vargas‐Origel 2004</a>; <a href="./references#CD001240-bbs2-0009" title="VelaphiS , MokhachaneM , MphahleleR , Beckh‐ArnoldE . Effect of prophylactic phenobarbital on seizures, encephalopathy and mortality in neonates with perinatal asphyxia. South African Journal of Child Health2013;7(1):17‐21. ">Velaphi 2013</a>). There was substantial heterogeneity of effect (I<sup>2</sup> = 78%). </p> <p>Meta‐analysis of the four trials conducted in low‐ or middle‐income countries showed a significant reduction in seizures in the experimental group compared to the control group (typical RR 0.49, 95% CI 0.33 to 0.73; typical RD ‐0.20, 95% CI ‐0.30 to ‐0.09; NNTB 5, 95% CI 3 to 11; 4 studies, 257 infants) (<a href="./references#CD001240-fig-0009" title="">Analysis 1.7</a>.4) (<a href="./references#CD001240-bbs2-0001" title="AvasiloaieiA , DimitriuC , MoscaluM , PaduraruL , StamatinM . High‐dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatrics International2013;55(5):589‐93. [PUBMED: 23659666] ">Avasiloaiei 2013</a>; <a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>; <a href="./references#CD001240-bbs2-0007" title="Vargas‐OrigelA , Espinosa‐GarciaJOG , Muniz‐QuezadaE , Vargas‐NietoMA , Aguilar‐GarciaG . Prevention of hypoxic‐ischemic encephalopathy with high‐dose, early phenobarbital therapy [Prevencion de la encefalopatia hipoxico‐isquemica mediante Fenobarbital en forma temprana y a dosis alta]. Gaceta Medica de Mexico2004;140(2):147‐53. [MEDLINE: 15162947] ">Vargas‐Origel 2004</a>; <a href="./references#CD001240-bbs2-0009" title="VelaphiS , MokhachaneM , MphahleleR , Beckh‐ArnoldE . Effect of prophylactic phenobarbital on seizures, encephalopathy and mortality in neonates with perinatal asphyxia. South African Journal of Child Health2013;7(1):17‐21. ">Velaphi 2013</a>). There was no evidence of heterogeneity of effect (I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD001240-sec-0073"> <h6 class="title">Adverse effects of barbiturate administration</h6> <section id="CD001240-sec-0074"> <p><b>Respiratory depression (outcome 1.8)</b></p> <p>Two trials comparing barbiturate (both phenobarbital) with conventional therapy reported on respiratory depression requiring intubation (<a href="./references#CD001240-bbs2-0002" title="GathwalaG , MarwahA , GahlautV , MarwahP . Effect of high‐dose phenobarbital on oxidative stress in perinatal asphyxia: an open label randomized controlled trial. Indian Pediatrics2011;48(8):613‐7. [PUBMED: 21169640] ">Gathwala 2011</a>; <a href="./references#CD001240-bbs2-0004" title="HallRT , HallFK , DailyDK . High‐dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three‐year follow‐up. Journal of Pediatrics1998;132(2):345‐8. [PUBMED: 9506654] ">Hall 1998</a>). There were 93 infants, of whom seven required intubation for respiratory depression. All of these infants were from the same trial (<a href="./references#CD001240-bbs2-0004" title="HallRT , HallFK , DailyDK . High‐dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three‐year follow‐up. Journal of Pediatrics1998;132(2):345‐8. [PUBMED: 9506654] ">Hall 1998</a>). There was no difference in respiratory depression requiring intubation between these two groups (typical RR 0.75, 95% CI 0.18 to 3.11; typical RD ‐0.02, 95% CI ‐0.14 to 0.09; 2 trials, 93 infants) (<a href="./references#CD001240-fig-0010" title="">Analysis 1.8</a>). </p> </section> <section id="CD001240-sec-0075"> <p><b>Hypotension requiring inotropic support (outcome 1.9)</b></p> <p>Only one trial comparing thiopentone with conventional therapy reported on hypotension requiring inotropic support (<a href="./references#CD001240-bbs2-0003" title="GoldbergRN , MoscosoP , BauerCR , BloomFL , CurlessRG , BurkeB , et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. Journal of Pediatrics1986;109(5):851‐6. [PUBMED: 3534201] ">Goldberg 1986</a>). There were 31 infants, of whom 21 required inotropic support. There was a statistically significant difference between the experimental and control groups in favor of the control (RR 1.88, 95% CI 1.06 to 3.32; RD 0.41, 95% CI 0.11 to 0.71; NNTH 7, 95% CI 1 to 9; 1 trial, 31 infants) (<a href="./references#CD001240-fig-0011" title="">Analysis 1.9</a>). Heterogeneity of effect was not applicable. </p> </section> </section> <section id="CD001240-sec-0076"> <h6 class="title">Post hoc outcomes</h6> <section id="CD001240-sec-0077"> <p><b>Abnormal neurologic exam (outcome 1.10)</b></p> <p>Four trials comparing phenobarbital with conventional therapy reported on abnormal neurologic exam at discharge (<a href="./references#CD001240-bbs2-0001" title="AvasiloaieiA , DimitriuC , MoscaluM , PaduraruL , StamatinM . High‐dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatrics International2013;55(5):589‐93. [PUBMED: 23659666] ">Avasiloaiei 2013</a>; <a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>; <a href="./references#CD001240-bbs2-0007" title="Vargas‐OrigelA , Espinosa‐GarciaJOG , Muniz‐QuezadaE , Vargas‐NietoMA , Aguilar‐GarciaG . Prevention of hypoxic‐ischemic encephalopathy with high‐dose, early phenobarbital therapy [Prevencion de la encefalopatia hipoxico‐isquemica mediante Fenobarbital en forma temprana y a dosis alta]. Gaceta Medica de Mexico2004;140(2):147‐53. [MEDLINE: 15162947] ">Vargas‐Origel 2004</a>; <a href="./references#CD001240-bbs2-0009" title="VelaphiS , MokhachaneM , MphahleleR , Beckh‐ArnoldE . Effect of prophylactic phenobarbital on seizures, encephalopathy and mortality in neonates with perinatal asphyxia. South African Journal of Child Health2013;7(1):17‐21. ">Velaphi 2013</a>). There were 245 infants, of whom 97 had an abnormal neurologic exam at discharge. None of the studies found a statistically significant difference between the experimental and control groups. Meta‐analysis of the four trials demonstrated a nonsignificant trend in favor of the experimental group compared to the control (typical RR 0.85, 95% CI 0.67 to 1.08; 4 trials, 245 infants) (very low quality evidence) (<a href="./references#CD001240-fig-0012" title="">Analysis 1.10</a>.1). There was substantial heterogeneity of effect (I<sup>2</sup> = 76%). </p> <p>Meta‐analysis of the three trials that identified results for the subset of infants with Sarnat 2 or greater for barbiturate versus control also showed a nonsignificant trend in favor of the experimental group compared to the control group (typical RR 0.76, 95% CI 0.54 to 1.08; 3 studies, 91 infants) (<a href="./references#CD001240-fig-0012" title="">Analysis 1.10</a>.2) (<a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>; <a href="./references#CD001240-bbs2-0007" title="Vargas‐OrigelA , Espinosa‐GarciaJOG , Muniz‐QuezadaE , Vargas‐NietoMA , Aguilar‐GarciaG . Prevention of hypoxic‐ischemic encephalopathy with high‐dose, early phenobarbital therapy [Prevencion de la encefalopatia hipoxico‐isquemica mediante Fenobarbital en forma temprana y a dosis alta]. Gaceta Medica de Mexico2004;140(2):147‐53. [MEDLINE: 15162947] ">Vargas‐Origel 2004</a>; <a href="./references#CD001240-bbs2-0009" title="VelaphiS , MokhachaneM , MphahleleR , Beckh‐ArnoldE . Effect of prophylactic phenobarbital on seizures, encephalopathy and mortality in neonates with perinatal asphyxia. South African Journal of Child Health2013;7(1):17‐21. ">Velaphi 2013</a>). There was no heterogeneity of effect (I<sup>2</sup> = 0%). </p> <p>Meta‐analysis of the four trials conducted in low‐ and middle‐income countries demonstrated a nonsignificant trend in favor of the experimental group compared to the control (typical RR 0.85, 95% CI 0.67 to 1.08; 4 trials, 245 infants) (<a href="./references#CD001240-fig-0012" title="">Analysis 1.10</a>.3) (<a href="./references#CD001240-bbs2-0001" title="AvasiloaieiA , DimitriuC , MoscaluM , PaduraruL , StamatinM . High‐dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatrics International2013;55(5):589‐93. [PUBMED: 23659666] ">Avasiloaiei 2013</a>; <a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>; <a href="./references#CD001240-bbs2-0007" title="Vargas‐OrigelA , Espinosa‐GarciaJOG , Muniz‐QuezadaE , Vargas‐NietoMA , Aguilar‐GarciaG . Prevention of hypoxic‐ischemic encephalopathy with high‐dose, early phenobarbital therapy [Prevencion de la encefalopatia hipoxico‐isquemica mediante Fenobarbital en forma temprana y a dosis alta]. Gaceta Medica de Mexico2004;140(2):147‐53. [MEDLINE: 15162947] ">Vargas‐Origel 2004</a>; <a href="./references#CD001240-bbs2-0009" title="VelaphiS , MokhachaneM , MphahleleR , Beckh‐ArnoldE . Effect of prophylactic phenobarbital on seizures, encephalopathy and mortality in neonates with perinatal asphyxia. South African Journal of Child Health2013;7(1):17‐21. ">Velaphi 2013</a>). There was substantial heterogeneity of effect (I<sup>2</sup> = 76%) </p> </section> </section> </section> </section> <section id="CD001240-sec-0078"> <h4 class="title">Barbiturate treatment compared to other barbiturate treatment</h4> <p>We found no trials comparing barbiturate versus other barbiturate.</p> </section> <section id="CD001240-sec-0079"> <h4 class="title">Barbiturate treatment compared to other nonbarbiturate anticonvulsant treatment</h4> <p>We found one RCT comparing barbiturate therapy to other nonbarbiturate anticonvulsant therapy, which compared barbiturate therapy to phenytoin (<a href="./references#CD001240-bbs2-0008" title="VelaF , DuranJA , ChungaF , SerranoJS , VallsA . Preventive treatment of convulsions in perinatal asphyxia [Tratamiento profilactico de convulsiones en asfixia perinatal]. Anales Espanoles de Pediatria1987;27(2):95‐9. [PUBMED: 3662273] ">Vela 1987</a>). </p> <section id="CD001240-sec-0080"> <h5 class="title">Primary outcomes</h5> <section id="CD001240-sec-0081"> <h6 class="title">Death or severe neurodevelopmental disability</h6> <p>The trial did not report death or severe neurodevelopmental disability.</p> </section> </section> <section id="CD001240-sec-0082"> <h5 class="title">Secondary outcomes</h5> <section id="CD001240-sec-0083"> <h6 class="title">Seizures within the neonatal period (outcome 2.1)</h6> <p>The trial comparing barbiturate therapy to other nonbarbiturate anticonvulsant therapy reported seizures in the neonatal period (<a href="./references#CD001240-bbs2-0008" title="VelaF , DuranJA , ChungaF , SerranoJS , VallsA . Preventive treatment of convulsions in perinatal asphyxia [Tratamiento profilactico de convulsiones en asfixia perinatal]. Anales Espanoles de Pediatria1987;27(2):95‐9. [PUBMED: 3662273] ">Vela 1987</a>). There were 17 infants, of whom two had seizures in the neonatal period. There was no significant difference in seizure activity in the neonatal period between the two study groups (RR 0.89, 95% CI 0.07 to 12.00; 1 trial, 17 infants) (<a href="./references#CD001240-fig-0013" title="">Analysis 2.1</a>). Heterogeneity of effect was not applicable. </p> <p>The trial reported no other relevant outcomes for this comparison.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001240-sec-0084" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001240-sec-0084"></div> <p>Outcome of infants with moderate‐to‐severe HIE has improved with the introduction of mild hypothermia (<a href="./references#CD001240-bbs2-0035" title="JacobsSE , BergM , HuntR , Tarnow‐MordiWO , InderTE , DavisPG . Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD003311.pub3; PUBMED: 23440789] ">Jacobs 2013</a>). Despite these advances, perinatal asphyxia remains an important cause of death and neurodevelopmental disability. The exploration of additional neuroprotective strategies remains an important clinical issue. </p> <p>In this review, we identified nine RCTs of prophylactic barbiturates for the prevention of morbidity and mortality in full term and late preterm infants with perinatal asphyxia. Eight of these studies compared prophylactic barbiturate therapy to conventional treatment (enrolling 439 infants) and one study compared barbiturate therapy to treatment with phenytoin (enrolling 17 infants). </p> <section id="CD001240-sec-0085"> <h3 class="title" id="CD001240-sec-0085">Prophylactic barbiturate treatment versus conventional treatment</h3> <p>Only one study reported on the composite primary outcome of mortality or severe neurodevelopmental disability (<a href="./references#CD001240-bbs2-0004" title="HallRT , HallFK , DailyDK . High‐dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three‐year follow‐up. Journal of Pediatrics1998;132(2):345‐8. [PUBMED: 9506654] ">Hall 1998</a>). This trial, which compared phenobarbital to conventional therapy, was small and did not blind allocation of the intervention. <a href="./references#CD001240-bbs2-0004" title="HallRT , HallFK , DailyDK . High‐dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three‐year follow‐up. Journal of Pediatrics1998;132(2):345‐8. [PUBMED: 9506654] ">Hall 1998</a> reported a significant reduction in the combined outcome of death or severe neurodevelopmental disability in infants treated with phenobarbital. </p> <p>Regarding the components of our primary outcome, eight trials comparing barbiturates with conventional therapy reported death (<a href="./references#CD001240-bbs2-0001" title="AvasiloaieiA , DimitriuC , MoscaluM , PaduraruL , StamatinM . High‐dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatrics International2013;55(5):589‐93. [PUBMED: 23659666] ">Avasiloaiei 2013</a>; <a href="./references#CD001240-bbs2-0002" title="GathwalaG , MarwahA , GahlautV , MarwahP . Effect of high‐dose phenobarbital on oxidative stress in perinatal asphyxia: an open label randomized controlled trial. Indian Pediatrics2011;48(8):613‐7. [PUBMED: 21169640] ">Gathwala 2011</a>; <a href="./references#CD001240-bbs2-0003" title="GoldbergRN , MoscosoP , BauerCR , BloomFL , CurlessRG , BurkeB , et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. Journal of Pediatrics1986;109(5):851‐6. [PUBMED: 3534201] ">Goldberg 1986</a>; <a href="./references#CD001240-bbs2-0004" title="HallRT , HallFK , DailyDK . High‐dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three‐year follow‐up. Journal of Pediatrics1998;132(2):345‐8. [PUBMED: 9506654] ">Hall 1998</a>; <a href="./references#CD001240-bbs2-0005" title="RuthV , KorkmanM , LiikanenA , PaetauR . High‐dose phenobarbitol treatment to prevent postasphyxial brain damage: a 6‐year follow up [abstract]. Pediatric Research1991;30:638. [DOI: 10.1203/00006450‐199112000‐00091] ">Ruth 1991</a>; <a href="./references#CD001240-bbs2-0006" title="SinghD , KumarP , MajumdarS , NarangA . Effect of phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy ‐ a randomized controlled trial. Journal of Perinatal Medicine2004;32(3):278‐81. [PUBMED: 15188805] SinghD , KumarP , NarangA . A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(6):391‐5. [PUBMED: 16390805] ">Singh 2004</a>; <a href="./references#CD001240-bbs2-0007" title="Vargas‐OrigelA , Espinosa‐GarciaJOG , Muniz‐QuezadaE , Vargas‐NietoMA , Aguilar‐GarciaG . Prevention of hypoxic‐ischemic encephalopathy with high‐dose, early phenobarbital therapy [Prevencion de la encefalopatia hipoxico‐isquemica mediante Fenobarbital en forma temprana y a dosis alta]. Gaceta Medica de Mexico2004;140(2):147‐53. [MEDLINE: 15162947] ">Vargas‐Origel 2004</a>; <a href="./references#CD001240-bbs2-0009" title="VelaphiS , MokhachaneM , MphahleleR , Beckh‐ArnoldE . Effect of prophylactic phenobarbital on seizures, encephalopathy and mortality in neonates with perinatal asphyxia. South African Journal of Child Health2013;7(1):17‐21. ">Velaphi 2013</a>). No studies found a statistically significant difference in mortality rates between the experimental and control groups and the meta‐analysis did not support any difference in mortality. </p> <p>Only one trial reported on major neurodevelopmental disability in survivors (<a href="./references#CD001240-bbs2-0004" title="HallRT , HallFK , DailyDK . High‐dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three‐year follow‐up. Journal of Pediatrics1998;132(2):345‐8. [PUBMED: 9506654] ">Hall 1998</a>). There were 31 infants in this trial, of whom 11 had severe neurodevelopmental disability. This study reported a significant reduction in severe neurodevelopmental disability in infants treated with phenobarbital. </p> <p>In the current review, the outcome of abnormal neurologic exam at the time of discharge was added post hoc. Though not statistically significant, meta‐analysis of the four trials that reported on this outcome showed a trend towards a reduction in the risk of an abnormal exam with the use of prophylactic barbiturate therapy compared to conventional therapy. This trend is of interest as an abnormal neurologic exam at discharge has been shown to be associated with a greater risk of death or disability (<a href="./references#CD001240-bbs2-0026" title="GunnAJ , WyattJS , WhitelawA , BarksJ , AzzopardiD , BallardR , et al. Therapeutic hypothermia changes the prognostic value of clinical evaluation of neonatal encephalopathy. Journal of Pediatrics2008;152(1):55‐8. [PUBMED: 18154900] ">Gunn 2008</a>; <a href="./references#CD001240-bbs2-0051" title="SarnatHB , SarnatMS . Neonatal encephalopathy following fetal distress. Archives of Neurology1976;33:696‐705. ">Sarnat 1976</a>; <a href="./references#CD001240-bbs2-0054" title="ShankaranS , LaptookAR , TysonJE , EhrenkranzRA , BannCM , DasA , et al. Evolution of encephalopathy during whole body hypothermia for neonatal hypoxic‐ischemic encephalopathy. Journal of Pediatrics2012;160(4):567‐72. [PUBMED: 22050871] ">Shankaran 2012</a>), and served as a better predictor of death or disability at 18 months of age than did the treatment group allocation (control versus hypothermia) in a secondary analysis of the National Institute of Child Health and Human Development (NICHD) trial of whole body hypothermia (<a href="./references#CD001240-bbs2-0054" title="ShankaranS , LaptookAR , TysonJE , EhrenkranzRA , BannCM , DasA , et al. Evolution of encephalopathy during whole body hypothermia for neonatal hypoxic‐ischemic encephalopathy. Journal of Pediatrics2012;160(4):567‐72. [PUBMED: 22050871] ">Shankaran 2012</a>). </p> <p>Most studies included in this review reported seizures within the neonatal period. Meta‐analysis of these trials demonstrated a significant reduction in the risk of seizures in infants treated with barbiturates soon after perinatal asphyxia when compared to those who received conventional therapy. In the overall analysis, we noted substantial heterogeneity (I<sup>2</sup> = 68%); however, this heterogeneity was not noted in the a priori subgroup analysis of the five trials that used phenobarbital. </p> <p>Though the reduction in seizures was significant, the clinical importance of this remains unclear. This reduction does not appear, from the limited data available in the current review, to translate into a reduction in the risk of developmental delay. In infants with HIE, clinical seizures may be associated with worse neurodevelopmental outcome, independent of HIE severity (<a href="./references#CD001240-bbs2-0021" title="GlassHC , GliddenD , JeremyRJ , BarkovichAJ , FerrieroDM , MillerSP . Clinical neonatal seizures are independently associated with outcome in infants at risk for hypoxic‐ischemic brain injury. Journal of Pediatrics2009;155(3):318‐23. [PUBMED: 19540512] ">Glass 2009</a>). In addition, post hoc analysis of data from the Cool‐Cap trial revealed that absence of seizures represented an independent predictor of better 18‐month outcome in asphyxiated neonates (<a href="./references#CD001240-bbs2-0060" title="WyattJS , GluckmanPD , LiuPY , AzzopardiD , BallardRA , EdwardsAD , et al. Determinants of outcomes after head cooling for neonatal encephalopathy. Pediatrics2007;119(5):912‐21. [PUBMED: 17473091] ">Wyatt 2007</a>). However, it is unknown whether the successful pharmacologic treatment of seizures can lead to improved neurodevelopmental outcome. </p> <p>The one trial that compared barbiturate therapy to other nonbarbiturate anticonvulsant therapy did not show a significant difference in the risk of seizures. </p> </section> <section id="CD001240-sec-0086"> <h3 class="title" id="CD001240-sec-0086">Prophylactic barbiturate treatment versus other prophylactic nonbarbiturate anticonvulsant treatment </h3> <p>There were no data reported for the primary outcome for the comparison of barbiturate therapy to other nonbarbiturate anticonvulsant therapy. One study reported on prophylactic barbiturate versus prophylactic phenytoin. There was no significant difference in seizure activity in the neonatal period between the two study groups. </p> </section> <section id="CD001240-sec-0087"> <h3 class="title" id="CD001240-sec-0087">Limitations</h3> <p>A sizable limitation to the current review is that none of the available trials included therapeutic hypothermia as part of standard or conventional management of these infants. Therapeutic hypothermia has been proven to decrease the risk of mortality and neurodevelopmental delay in infants with early moderate‐to‐severe encephalopathy and has become the standard of care (<a href="./references#CD001240-bbs2-0035" title="JacobsSE , BergM , HuntR , Tarnow‐MordiWO , InderTE , DavisPG . Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD003311.pub3; PUBMED: 23440789] ">Jacobs 2013</a>). This limits our ability to generalize to this population of infants who will receive therapeutic hypothermia. Issues to consider are the pharmacokinetics of phenobarbital during therapeutic hypothermia and the potential for exacerbation of the potential negative effects of phenobarbital administration. However, it may also be that phenobarbital, in the context of therapeutic hypothermia, may provide additional benefit. Phenobarbital administration prior to cooling is associated with an altered temperature profile during induction, with infants reaching goal temperature more quickly compared to infants who did not receive phenobarbital (<a href="./references#CD001240-bbs2-0050" title="Sant'AnnaG , LaptookAR , ShankaranS , BaraR , McDonaldSA , HigginsRD , et al. Phenobarbital and temperature profile during hypothermia for hypoxic‐ischemic encephalopathy. Journal of Child Neurology2012;27(4):451‐7. [PUBMED: 21960671] ">Sant'Anna 2012</a>). </p> <p>Only one study utilized newer bedside technologies for the diagnosis and management of seizures (<a href="./references#CD001240-bbs2-0001" title="AvasiloaieiA , DimitriuC , MoscaluM , PaduraruL , StamatinM . High‐dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatrics International2013;55(5):589‐93. [PUBMED: 23659666] ">Avasiloaiei 2013</a>). Use of aEEG has been increasing as it is readily available at the bedside for immediate assessment of infants and is more readily interpreted without specialized expertise. This use is controversial as it is subject to artefact, and has fewer electrodes than full channel EEG, resulting in potential underdiagnosis of seizure burden (<a href="./references#CD001240-bbs2-0055" title="ShellhaasRA , SoaitaAI , ClancyRR . Sensitivity of amplitude‐integrated electroencephalography for neonatal seizure detection. Pediatrics2007;120(4):770‐7. [PUBMED: 17908764] ">Shellhaas 2007</a>; <a href="./references#CD001240-bbs2-0059" title="WusthoffCJ , ShellhaasRA , ClancyRR . Limitations of single‐channel EEG on the forehead for neonatal seizure detection. Journal of Perinatology2009;29(3):237‐42. [PUBMED: 19052554] ">Wusthoff 2009</a>). Nonetheless, given that infants with suspected seizure are routinely monitored by aEEG, use of this modality should be included in studies assessing seizure burden and barbiturate use. </p> <p>In addition, no uniform definition of perinatal asphyxia was used between studies. In the absence of a valid practical single marker of a hypoxic‐ischemic insult (with potential to cause significant cerebral injury), researchers should strive to use consensus based diagnostic criteria and endeavor to collect data relating to the markers in the neonatal period known at present to be associated with a poor neurodevelopmental outcome (e.g. MRI, EEG data, etc.). It is also important for future research to identify other early and reliable markers associated with greatest risk of asphyxial cerebral injury, in order that potential neuroprotective strategies, commenced soon after birth, can be assessed. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001240-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/urn:x-wiley:14651858:media:CD001240:CD001240-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_t/tCD001240-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram: review update." data-id="CD001240-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_n/nCD001240-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram: review update.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/full#CD001240-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_n/nCD001240-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001240-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/urn:x-wiley:14651858:media:CD001240:CD001240-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_t/tCD001240-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Barbiturates versus control, outcome: 1.7 Seizures within neonatal period." data-id="CD001240-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_n/nCD001240-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Barbiturates versus control, outcome: 1.7 Seizures within neonatal period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/full#CD001240-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_n/nCD001240-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001240-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/urn:x-wiley:14651858:media:CD001240:CD001240-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_t/tCD001240-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Barbiturates versus control, Outcome 1 Death or major neurodevelopmental disability." data-id="CD001240-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_n/nCD001240-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Barbiturates versus control, Outcome 1 Death or major neurodevelopmental disability. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/references#CD001240-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_n/nCD001240-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001240-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/urn:x-wiley:14651858:media:CD001240:CD001240-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_t/tCD001240-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Barbiturates versus control, Outcome 2 Death." data-id="CD001240-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_n/nCD001240-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Barbiturates versus control, Outcome 2 Death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/references#CD001240-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_n/nCD001240-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001240-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/urn:x-wiley:14651858:media:CD001240:CD001240-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_t/tCD001240-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Barbiturates versus control, Outcome 3 Major neurodevelopmental disability in survivors examined." data-id="CD001240-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_n/nCD001240-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Barbiturates versus control, Outcome 3 Major neurodevelopmental disability in survivors examined. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/references#CD001240-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_n/nCD001240-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001240-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/urn:x-wiley:14651858:media:CD001240:CD001240-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_t/tCD001240-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Barbiturates versus control, Outcome 4 Cerebral palsy." data-id="CD001240-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_n/nCD001240-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Barbiturates versus control, Outcome 4 Cerebral palsy.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/references#CD001240-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_n/nCD001240-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001240-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/urn:x-wiley:14651858:media:CD001240:CD001240-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_t/tCD001240-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Barbiturates versus control, Outcome 5 Developmental delay in survivors examined." data-id="CD001240-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_n/nCD001240-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Barbiturates versus control, Outcome 5 Developmental delay in survivors examined. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/references#CD001240-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_n/nCD001240-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001240-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/urn:x-wiley:14651858:media:CD001240:CD001240-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_t/tCD001240-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Barbiturates versus control, Outcome 6 IQ in survivors." data-id="CD001240-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_n/nCD001240-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Barbiturates versus control, Outcome 6 IQ in survivors.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/references#CD001240-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_n/nCD001240-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001240-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/urn:x-wiley:14651858:media:CD001240:CD001240-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_t/tCD001240-CMP-001-07.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Barbiturates versus control, Outcome 7 Seizures within neonatal period." data-id="CD001240-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_n/nCD001240-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Barbiturates versus control, Outcome 7 Seizures within neonatal period.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/references#CD001240-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_n/nCD001240-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001240-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/urn:x-wiley:14651858:media:CD001240:CD001240-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_t/tCD001240-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Barbiturates versus control, Outcome 8 Respiratory depression." data-id="CD001240-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_n/nCD001240-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Barbiturates versus control, Outcome 8 Respiratory depression.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/references#CD001240-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_n/nCD001240-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001240-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/urn:x-wiley:14651858:media:CD001240:CD001240-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_t/tCD001240-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Barbiturates versus control, Outcome 9 Hypotension requiring inotropic support." data-id="CD001240-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_n/nCD001240-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Barbiturates versus control, Outcome 9 Hypotension requiring inotropic support. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/references#CD001240-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_n/nCD001240-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001240-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/urn:x-wiley:14651858:media:CD001240:CD001240-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_t/tCD001240-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Barbiturates versus control, Outcome 10 Abnormal neurologic exam at discharge." data-id="CD001240-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_n/nCD001240-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Barbiturates versus control, Outcome 10 Abnormal neurologic exam at discharge.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/references#CD001240-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_n/nCD001240-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001240-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/urn:x-wiley:14651858:media:CD001240:CD001240-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_t/tCD001240-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Phenobarbital versus phenytoin, Outcome 1 Seizures within the first 7 days of age." data-id="CD001240-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_n/nCD001240-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Phenobarbital versus phenytoin, Outcome 1 Seizures within the first 7 days of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/references#CD001240-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/media/CDSR/CD001240/image_n/nCD001240-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001240-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Barbiturate treatment compared to placebo or no treatment</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Barbiturate treatment compared to placebo or no treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> infants with perinatal asphyxia<br/> <b>Setting:</b> neonatal intensive care<br/> <b>Intervention:</b> prophylactic barbiturate<br/> <b>Comparison:</b> no treatment or selective barbiturate treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with selective barbiturate treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with prophylactic barbiturate</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death or major neurodevelopmental disability<br/> follow‐up: &gt; 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.33<br/> (0.14 to 0.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>31<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Very low quality</p> <p><sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Risk of bias: unblinded study; concern regarding performance bias, detection bias, and incomplete follow‐up. Imprecision: 95% CI were wide and imprecise </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>813 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>268 per 1000<br/> (114 to 634) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/> (0.55 to 1.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>429<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low quality</p> <p><sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Risk of bias: unblinded studies; concern regarding performance bias and detection bias. Imprecision: 95% CI were wide and imprecise </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>145 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>128 per 1000<br/> (80 to 206) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major neurodevelopmental disability<br/> follow‐up: &gt; 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.24<br/> (0.06 to 0.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>31<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Very low quality</p> <p><sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Risk of bias: unblinded study; concern regarding performance bias, detection bias, and incomplete follow‐up. Imprecision: 95% CI were wide and imprecise </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>563 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>135 per 1000<br/> (34 to 518) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cerebral palsy</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.58<br/> (0.19 to 1.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>69<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Very low quality</p> <p><sup>1, 2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Risk of bias: unblinded studies; concern regarding performance bias and detection bias. Imprecision: 95% CI were wide and imprecise. Inconsistency: clinically important heterogeneity noted </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>242 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>141 per 1000<br/> (46 to 412) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Developmental delay</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.54<br/> (0.24 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>63<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Very low quality</p> <p><sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Risk of bias: unblinded studies; concern regarding performance bias and detection bias. Imprecision: 95% CI were wide and imprecise </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>355 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>192 per 1000<br/> (85 to 422) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Seizures (clinical or electrographic)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.62<br/> (0.48 to 0.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>319<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low quality</p> <p><sup>1, 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Risk of bias: unblinded studies; concern regarding performance bias and detection bias. Inconsistency: statistical heterogeneity noted </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>474 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>294 per 1000<br/> (228 to 384) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Abnormal neurologic exam at discharge</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.85<br/> (0.67 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>245<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low quality</p> <p><sup>1, 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Risk of bias: unblinded studies; concern regarding performance bias and detection bias. Inconsistency: statistical heterogeneity noted </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>432 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>367 per 1000<br/> (290 to 467) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded for possible performance and detection bias. </p> <p><sup>2</sup> Imprecision: wide CIs. Sample size below optimal information size. </p> <p><sup>3</sup> Clinically important heterogeneity noted. </p> <p><sup>4</sup> I<sup>2</sup> = 68%. </p> <p><sup>5</sup> I<sup>2</sup> = 76%. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Barbiturate treatment compared to placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/full#CD001240-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001240-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Barbiturates versus control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death or major neurodevelopmental disability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Phenobarbital vs. control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.14, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Any barbiturate vs. control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.55, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Phenobarbital vs. control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.48, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Any barbiturate in infants with Sarnat 2 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.45, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Studies in low‐ and middle‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.42, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Major neurodevelopmental disability in survivors examined <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Phenobarbital vs. control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.06, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Cerebral palsy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Phenobarbital vs. control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.19, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Developmental delay in survivors examined <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Any barbiturate vs. control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.24, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Phenobarbital vs. control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.02, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Thiopentone vs. control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.36, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Any barbiturate in infants with Sarnat 2 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.36, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Studies in low‐ and middle‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.02, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 IQ in survivors <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Seizures within neonatal period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Any barbiturate vs. control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.48, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Phenobarbital vs. control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.38, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Any barbiturate in infants with Sarnat 2 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.47, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Studies in low‐ and middle‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.33, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Respiratory depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Phenobarbital vs. control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.18, 3.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Studies in low‐ and middle‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Hypotension requiring inotropic support <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Thiopentone vs. control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [1.06, 3.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Abnormal neurologic exam at discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Phenobarbital vs. control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.67, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Any barbiturate in infants with Sarnat 2 to 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.54, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Studies in low‐ and middle‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.67, 1.08]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Barbiturates versus control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/references#CD001240-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001240-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Phenobarbital versus phenytoin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Seizures within the first 7 days of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.07, 12.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Phenobarbital versus phenytoin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001240.pub3/references#CD001240-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001240.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD001240-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001240-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD001240-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD001240-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD001240-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001240\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001240\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001240\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001240\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001240\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001240\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001240\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001240\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001240\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001240\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001240\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001240\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001240\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001240\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001240\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001240\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001240\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001240\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=VXKc2U6b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001240.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001240.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001240.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001240.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001240.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716446717"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001240.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716446720"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001240.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d9fb9fe219368',t:'MTc0MDcxNjQ0Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 